CUMULATIVE
SUPPLEMENT 9
SEPTEMBER 2000



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

20TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGEMENT AND SERVICES

2000

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

20TH EDITION

Cumulative Supplement 9

September 2000

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

20TH EDITION

CUMULATIVE SUPPLEMENT 9
SEPTEMBER 2000

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 20th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>DLT>** (DELETE) to the left of the line. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 20h Edition List will then be added to the "Discontinued Drug Product List" appearing in the 21st Edition.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When

this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
GALDERMA LABS INC (GALDERMA)	GALDERMA LABORATORIES LP (GALDERMA LABS LP)
GLOBAL PHARMACEUTICAL CORP (GLOBAL PHARM)	IMPAX LABORATORIES INC (IMPAX LABS)
HOECHST MARION ROUSSEL INC (HOECHST MARION RSSL)	AVENTIS PHARMACEUTICALS INC (AVENTIS PHARMS)
RHONE POULENC RORER PHARMACEUTICALS INC (RHONE POULENCE RORER)	AVENTIS PHARMACEUTICALS PRODUCTS INC (AVENTIS PHARM PROD)
ROCHE GLOBAL DEVELOPMENT (ROCHE GLOBAL)	ROCHE GLOBAL A DIVISION OF SYNTEX (USA) LLC (ROCHE GLOBAL DEV)
SYNTEX (USA) INC (SYNTEX)	SYNTEX (USA) LLC (SYNTEX (USA) LLC)
SYNTEX FP INC (SYNTEX)	SYNTEX (USA) LLC (SYNTEX (USA) LLC)
SYNTEX LABORATORIES INC SUB SYNTEX CORP (SYNTEX)	SYNTEX (USA) LLC (SYNTEX (USA) LLC)
SYNTEX USA INC (SYNTEX)	SYNTEX (USA) LLC (SYNTEX (USA) LLC)
TAP HOLDINGS INC (TAP HOLDINGS)	TAP PHARMACEUTICAL PRODUCTS INC (TAP PHARM)
ZENECA INC (ZENECA)	ASTRAZENECA PHARMACEUTICALS LP (ASTRAZENECA PHARMS)
ZENECA LTD (ZENECA)	ASTRAZENECA UK LTD (ASTRAZENECA UK)
ZENECA PHARMACEUTICALS DIV ZENECA INC (ZENECA)	ASTRAZENECA PHARMACEUTICALS LP (ASTRAZENECA PHARMS)

1.3 DICLOFENAC SODIUM OPHTHALMIC SOLUTION 0.1%

Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Falcon Pharms' (Alcon) NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

1.4 AVAILABILITY OF THE EDITION

The 20th Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $101.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at
http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at
http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 20th annual edition of the 1999 Orange Book Patent and Exclusivity List is at http://www.fda.gov/cder/orange/20bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at http://www.fda.gov/cder/orange/supplement/patents.pdf.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
http://www.fda.gov/cder/orange/patdecl.pdf
http://www.fda.gov/cder/orange/patdecl.html

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1999) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1999	MAR 2000	JUN 2000	SEP 2000
DRUG PRODUCTS LISTED	10045	10082	10186	10332
SINGLE SOURCE	2599 (25.9%)	2596 (25.7%)	2617 (25.7%)	2662 (25.8%)
MULTISOURCE	7335 (73.0%)	7375 (73.2%)	7458 (73.2%)	7560 (73.2%)
THERAPEUTICALLY EQUIVALENT	6986 (69.5%)	7040 (69.8%)	7132 (70.0%)	7238 (70.1%)
NOT THERAPEUTICALLY EQUIVALENT	349 (3.5%)	335 (3.3%)	326 (3.2%)	322 (3.1%)
EXCEPTIONS[1]	111 (1.1%)	111 (1.1%)	111 (1.1%)	110 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	0	6	11	7
NUMBER OF APPLICANTS	576	575	580	587

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL
PHRENILIN FORTE

AB	+	AMARIN PHARMS	650MG;50MG	N88831 001 JUN 19, 1985		
AB	+	CARNRICK	650MG;50MG	N88831 001 JUN 19, 1985	> DLT >	> DLT >

TABLET; ORAL
PHRENILIN

AB	+	AMARIN PHARMS	325MG;50MG	N87811 001 JUN 19, 1985		
AB	+	CARNRICK	325MG;50MG	N87811 001 JUN 19, 1985		

ACETAMINOPHEN; CODEINE PHOSPHATE

SUSPENSION; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		AMARIN PHARMS	120MG/5ML;12MG/5ML	N86024 001		
AA		CARNRICK	120MG/5ML;12MG/5ML	N86024 001		

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		BARR	500MG;2.5MG	N40307 001 JUL 26, 2000		
AA			500MG;5MG	N40308 001 JUL 26, 2000		
AA			500MG;7.5MG	N40307 002 JUL 26, 2000		
AA			500MG;10MG	N40309 001 JUL 26, 2000		
AA			650MG;7.5MG	N40307 003 JUL 26, 2000		
AA			650MG;10MG	N40307 004 JUL 26, 2000		
AA			750MG;7.5MG	N40308 002 JUL 26, 2000		
AA		MALLINCKRODT	325MG;7.5MG	N40405 001 SEP 08, 2000	> ADD >	> ADD >
AA			325MG;10MG	N40400 001 JUL 26, 2000		
AA	+	UCB	325MG;7.5MG	N40248 001 APR 28, 2000	> ADD >	> ADD >

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		UCB	325MG;10MG	N40248 002 APR 28, 2000		
AA	+		325MG;7.5MG	N40248 001 APR 28, 2000	> DLT >	> DLT >
AA		VINTAGE PHARMS	325MG;10MG	N40355 001 MAY 31, 2000		
AA			500MG;10MG	N40356 001 MAY 31, 2000		
AA			660MG;10MG	N40358 001 MAY 31, 2000		
AA		WATSON LABS	660MG;10MG	N40094 003 AUG 08, 2000		

LORTAB

	@	UCB	325MG;5MG	N40099 001 JUN 25, 1997	> DLT >	> DLT >
	+		325MG;5MG	N40099 001 JUN 25, 1997	> ADD >	> ADD >

NORCO

AA	+	WATSON LABS	325MG;10MG	N40148 001 FEB 14, 1997		
	+		325MG;10MG	N40148 001 FEB 14, 1997		

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
PENTAZOCINE HCL AND ACETAMINOPHEN

AB		WATSON LABS	650MG;EQ 25MG BASE	N74699 001 MAR 24, 2000

TALACEN

AB	+	SANOFI SYNTHELABO	650MG;EQ 25MG BASE	N18458 001 SEP 23, 1982
	+		650MG;EQ 25MG BASE	N18458 001 SEP 23, 1982

ACETOHEXAMIDE

TABLET; ORAL
ACETOHEXAMIDE

AB		BARR	500MG	N70870 001 FEB 09, 1987
AB	+		500MG	N70870 001 FEB 09, 1987

ACETOHEXAMIDE

TABLET; ORAL

	DYMELOR			
AB	LILLY	250MG	N13378 002	
AB	*	500MG	N13378 001	
	@	250MG	N13378 002	
	@	500MG	N13378 001	

ACYCLOVIR

CAPSULE; ORAL

	ACYCLOVIR		
AB	ROXANE	200MG	N74570 002 APR 22, 1997
	@	200MG	N74570 002 APR 22, 1997

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

	ACYCLOVIR SODIUM		
AP	APOTHECON	EQ 500MG BASE/VIAL	N74897 001 FEB 27, 1998
AP		EQ 1GM BASE/VIAL	N74897 002 FEB 27, 1998
	@	EQ 500MG BASE/VIAL	N74897 001 FEB 27, 1998
	@	EQ 1GM BASE/VIAL	N74897 002 FEB 27, 1998

ADAPALENE

CREAM; TOPICAL

	DIFFERIN		
+	GALDERMA LABS LP	0.1%	N20748 001 MAY 26, 2000

ALBUMIN HUMAN

INJECTABLE; INJECTION

	OPTISON		
+	MALLINCKRODT	10MG/ML	N20899 001 DEC 31, 1997

ALBUMIN HUMAN

INJECTABLE; INJECTION

	OPTISON		
*	MOLECULAR BIOSYSTEMS	10MG/ML	N20899 001 DEC 31, 1997

ALBUTEROL

AEROSOL, METERED; INHALATION

	ALBUTEROL		
AB	MEDISOL	0.09MG/INH	N74072 001 AUG 01, 1996
AB	SIDMAK LABS CA	0.09MG/INH	N74072 001 AUG 01, 1996

ALBUTEROL SULFATE

SOLUTION; INHALATION

	ALBUTEROL SULFATE		
AN	BAUSCH AND LOMB	EQ 0.083% BASE	N75358 001 MAR 29, 2000

TABLET; ORAL

	ALBUTEROL SULFATE		
AB	MD PHARM	EQ 2MG BASE	N73120 001 SEP 29, 1992
AB		EQ 4MG BASE	N73121 001 SEP 29, 1992
	@ MEDEVA PHARMS CA	EQ 2MG BASE	N73120 001 SEP 29, 1992
	@	EQ 4MG BASE	N73121 001 SEP 29, 1992

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

	LOTRONEX		
+	GLAXO WELLCOME	EQ 1MG BASE	N21107 001 FEB 09, 2000

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

INJECTABLE; INJECTION
MULTI-12
\+ SABEX — 2 IU/ML;20MG/ML;12 UGM/ML;40 IU/ML; 1 UGM/ML;3MG/ML;80 UGM/ML;8MG/ML; 0.8MG/ML;0.72MG/ML;0.6MG/ML; 600 IU/ML — N21163 001 MAY 18, 2000

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM

AB	ROXANE	0.25MG	N74199 001 OCT 19, 1993
AB		0.5MG	N74199 002 OCT 19, 1993
AB		1MG	N74199 003 OCT 19, 1993
@		0.25MG	N74199 001 OCT 19, 1993
@		0.5MG	N74199 002 OCT 19, 1993
@		1MG	N74199 003 OCT 19, 1993

ALTRETAMINE

CAPSULE; ORAL
HEXALEN

\+	MEDIMMUNE ONCOLOGY	50MG	N19926 001 DEC 26, 1990
\+	US BIOSCIENCE	50MG	N19926 001 DEC 26, 1990

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
AMANTADINE HCL

AB	GENEVA PHARMS TECH	100MG	N71293 001 FEB 18, 1987

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
AMANTADINE HCL

AB	INVAMED	100MG	N71293 001 FEB 18, 1987

AMIFOSTINE

INJECTABLE; INJECTION
ETHYOL

\+	MEDIMMUNE ONCOLOGY	500MG/VIAL	N20221 001 DEC 08, 1995
\+	US BIOSCIENCE	500MG/VIAL	N20221 001 DEC 08, 1995

AMINO ACIDS

INJECTABLE; INJECTION
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER

	BAXTER HLTHCARE	15%	N20107 001 FEB 05, 1993
@		15%	N20107 001 FEB 05, 1993

TROPHAMINE

	B BRAUN	6%	N19018 001 JUL 20, 1984
\+		6%	N19018 001 JUL 20, 1984

TROPHAMINE 10%

	B BRAUN	10%	N19018 003 SEP 07, 1988
\+		10%	N19018 003 SEP 07, 1988

AMINOPHYLLINE

TABLET; ORAL
AMINOPHYLLINE

AB	GLOBAL PHARM	100MG	N84574 001
AB		200MG	N84576 001
@	IMPAX LABS	100MG	N84574 001
@		200MG	N84576 001

AMIODARONE HYDROCHLORIDE

TABLET; ORAL
AMIODARONE HCL

+	EON	400MG	N75315 002 JUN 30, 2000	> DLT > > DLT > > ADD > > ADD >	

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HCL

AB	MD PHARM	10MG	N85864 001	
AB		25MG	N85935 001	
AB		50MG	N85936 001	
AB		75MG	N86337 001	
AB		100MG	N86336 001	
AB		150MG	N86335 001	
@	MEDEVA PHARMS CA	10MG	N85864 001	
@		25MG	N85935 001	
@		50MG	N85936 001	
		75MG	N86337 001	
@		100MG	N86336 001	
@		150MG	N86335 001	

AMOXICILLIN

TABLET; ORAL
AMOXICILLIN

> ADD >					
> ADD >	AB	TEVA	500MG	N65056 001	
> ADD >				SEP 18, 2000	
> ADD >	AB		875MG	N65056 002	
> ADD >				SEP 18, 2000	
		AMOXIL			
> ADD >	AB	SMITHKLINE BEECHAM	500MG	N50754 002	
> ADD >				JUL 10, 1998	
> ADD >	AB +		875MG	N50754 001	
> ADD >				JUL 10, 1998	
> DLT >			500MG	N50754 002	
> DLT >				JUL 10, 1998	
> DLT >	*		875MG	N50754 001	
> DLT >				JUL 10, 1998	

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL
AUGMENTIN '500'

*	SMITHKLINE BEECHAM	500MG;EQ 125MG BASE	N50564 002 AUG 06, 1984	
		500MG;EQ 125MG BASE	N50564 002 AUG 06, 1984	

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
ADDERALL 12.5

	SHIRE LABS	3.125MG;3.125MG;3.125MG; 3.125MG	N11522 012 AUG 31, 2000

ADDERALL 15

	SHIRE LABS	3.75MG;3.75MG;3.75MG; 3.75MG	N11522 013 AUG 31, 2000

ADDERALL 7.5

+	SHIRE LABS	1.875MG;1.875MG;1.875MG; 1.875MG	N11522 011 AUG 31, 2000

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL
AGRYLIN

	ROBERTS LABS	EQ 0.5MG BASE	N20333 001 MAR 14, 1997
*		EQ 1MG BASE	N20333 002 MAR 14, 1997
	SHIRE LABS	EQ 0.5MG BASE	N20333 001 MAR 14, 1997
+		EQ 1MG BASE	N20333 002 MAR 14, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION
NORMIFLO

+	PHARMACIA AND UPJOHN	5,000 UNITS/0.5ML	N20227 002 MAY 23, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION
NORMIFLO
+ PHARMACIA AND UPJOHN 10,000 UNITS/0.5ML N20227 001 MAY 23, 1997
+ WYETH AYERST 5,000 UNITS/0.5ML N20227 002 MAY 23, 1997
+ 10,000 UNITS/0.5ML N20227 001 MAY 23, 1997

ARGATROBAN

INJECTABLE; INJECTION
ACOVA
+ TX BIOTECH 100MG/ML N20883 001 JUN 30, 2000

> ADD > ARSENIC TRIOXIDE

> ADD > INJECTABLE; INJECTION
> ADD > TRISENOX
> ADD > + CELL THERAP 1MG/ML N21248 001 SEP 25, 2000

ARTICAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION
SEPTOCAINE
+ DEPROCO 4%;EQ 0.01MG BASE/ML N20971 001 APR 03, 2000

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION
KABIVITE PED P + W KIT
+ FRESENIUS KABI N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A, 0.001MG/VIAL;400 IU/10ML,N/A;N/A, 0.14MG/VIAL;N/A,17MG/VIAL;N/A, 5MG/VIAL;0.2MG/10ML,N/A;N/A, 1MG/VIAL;N/A,1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML, N/A;7 IU/10ML,N/A N20176 001 DEC 29, 1993

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION
VITAPED
@ FRESENIUS KABI N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A, 0.001MG/VIAL;400 IU/10ML,N/A;N/A, 0.14MG/VIAL;N/A,17MG/VIAL;N/A, 5MG/VIAL;0.2MG/10ML,N/A;N/A, 1MG/VIAL;N/A,1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML, N/A;7 IU/10ML,N/A N20176 001 DEC 29, 1993

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL
MALARONE
+ GLAXO WELLCOME 250MG;100MG N21078 001 JUL 14, 2000
MALARONE PEDIATRIC
+ GLAXO WELLCOME 62.5MG;25MG N21078 002 JUL 14, 2000

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL
MOTOFEN
+ AMARIN PHARMS 0.025MG;1MG N17744 002
+ CARNRICK 0.025MG;1MG N17744 002
MOTOFEN HALF-STRENGTH
@ AMARIN PHARMS 0.025MG;0.5MG N17744 001
@ CARNRICK 0.025MG;0.5MG N17744 001

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE
AA PAR PHARM 0.025MG;2.5MG N40357 001 MAY 02, 2000

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
ENLON-PLUS

+	BAXTER PHARM PROD	0.14MG/ML;10MG/ML	N19677 001	NOV 06, 1991
+		0.14MG/ML;10MG/ML	N19678 001	NOV 06, 1991
*	OHMEDA	0.14MG/ML;10MG/ML	N19677 001	NOV 06, 1991
*		0.14MG/ML;10MG/ML	N19678 001	NOV 06, 1991

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OPTIVAR

+	ASTA	0.05%	N21127 001	MAY 22, 2000

BALSALAZIDE DISODIUM

CAPSULE; ORAL
COLAZAL

+	SALIX	750MG	N20610 001	JUL 18, 2000

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION
QVAR 40

>ADD<	+	3M	0.04MG/INH	N20911 002 SEP 15, 2000

QVAR 80

>ADD<	+	3M	0.08MG/INH	N20911 001 SEP 15, 2000

BENZTROPINE MESYLATE

TABLET; ORAL
BENZTROPINE MESYLATE

AA	GENEVA PHARMS TECH	**0.5MG**	**N72264 001**	FEB 27, 1989
AA		**1MG**	**N72265 001**	FEB 27, 1989

BENZTROPINE MESYLATE

TABLET; ORAL
BENZTROPINE MESYLATE

AA	GENEVA PHARMS TECH	**2MG**	**N72266 001**	FEB 27, 1989
AA	INVAMED	**0.5MG**	**N72264 001**	FEB 27, 1989
AA		**1MG**	**N72265 001**	FEB 27, 1989
AA		**2MG**	**N72266 001**	FEB 27, 1989

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
BETAXOLOL

AT	AKORN	**EQ 0.5% BASE**	**N75386 001**	JUN 30, 2000
>ADD< **AT**	NOVEX	**EQ 0.5% BASE**	**N75446 001**	SEP 28, 2000

BETOPTIC

AT	+ ALCON	**EQ 0.5% BASE**	**N19270 001**	AUG 30, 1985
	*	EQ 0.5% BASE	N19270 001	AUG 30, 1985

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION
URECHOLINE

	+ MERCK	5MG/ML	N06536 001	
	@	5MG/ML	N06536 001	

TABLET; ORAL
BETHANECHOL CHLORIDE

AA	DANBURY PHARMA	**10MG**	**N84408 001**	
AA		**25MG**	**N84441 001**	
AA		**50MG**	**N87444 001**	
	@	10MG	N84408 001	
	@	25MG	N84441 001	
	@	50MG	N87444 001	

DUVOID

AA	ROBERTS LABS	**10MG**	**N86262 001**	
AA		**25MG**	**N86263 001**	
AA		**50MG**	**N85882 003**	
	@	10MG	N86262 001	

BETHANECHOL CHLORIDE

TABLET; ORAL

		DUVOID					
		@ ROBERTS LABS	25MG	N86263 001	> ADD >		
		@	50MG	N85882 003	> ADD >		
		MYOTONACHOL			> ADD >		
AA		GLENWOOD	5MG	N84188 001	> ADD >		
AA			10MG	N84188 003	> ADD >		
AA			25MG	N84188 004	> ADD >		
	@		5MG	N84188 001	> ADD >		
	@		10MG	N84188 003	> ADD >		
	@		25MG	N84188 004	> ADD >		
		URECHOLINE			> ADD >		
AA	+	MERCK	5MG	N06536 003	> ADD >		
AA	+		10MG	N06536 002	> ADD >		
AA	+		25MG	N06536 004	> ADD >		
AA	+		50MG	N06536 005	> ADD >		
	@		5MG	N06536 003	> ADD >		
	@		10MG	N06536 002	> ADD >		
	@		25MG	N06536 004	> ADD >		
	@		50MG	N06536 005	> ADD >		
	+	ODYSSEY PHARMS	5MG	N89095 001	> ADD >		
				DEC 19, 1985	> ADD >		
	+		10MG	N88440 001	> ADD >		
				MAY 29, 1984	> ADD >		
	+		25MG	N88441 001	> ADD >		
				MAY 29, 1984	> ADD >		
	+		50MG	N89096 001	> ADD >		
				DEC 19, 1985	> ADD >		
AA	+	SIDMAK LABS NJ	5MG	N89095 001	> ADD >		
				DEC 19, 1985	> ADD >		
AA	+		10MG	N88440 001	> ADD >		
				MAY 29, 1984	> ADD >		
AA	+		25MG	N88441 001	> ADD >		
				MAY 29, 1984	> ADD >		
AA	+		50MG	N89096 001	> ADD >		
				DEC 19, 1985	> ADD >		

BEXAROTENE

GEL; TOPICAL

		TARGRETIN			> ADD >		
	+	LIGAND	1%	N21056 001	> ADD >		
				JUN 28, 2000	> ADD >		
					> ADD >		
					> DLT >		
					> DLT >		

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

		BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE					
		CHELSEA LABS	2.5MG;6.25MG	N75469 001	> ADD >	AB	
				SEP 25, 2000	> ADD >		
			5MG;6.25MG	N75469 002	> ADD >	AB	
				SEP 25, 2000	> ADD >		
			10MG;6.25MG	N75469 003	> ADD >	AB	
				SEP 25, 2000	> ADD >		
		EON	2.5MG;6.25MG	N75579 001	> ADD >	AB	
				SEP 25, 2000	> ADD >		
			5MG;6.25MG	N75579 002	> ADD >	AB	
				SEP 25, 2000	> ADD >		
			10MG;6.25MG	N75579 003	> ADD >	AB	
				SEP 25, 2000	> ADD >		
		INVAMED	2.5MG;6.25MG	N75527 001	> ADD >	AB	
				SEP 25, 2000	> ADD >		
			5MG;6.25MG	N75527 003	> ADD >	AB	
				SEP 25, 2000	> ADD >		
			10MG;6.25MG	N75527 002	> ADD >	AB	
				SEP 25, 2000	> ADD >		
		MYLAN	2.5MG;6.25MG	N75768 001	> ADD >	AB	
				SEP 25, 2000	> ADD >		
			5MG;6.25MG	N75768 002	> ADD >	AB	
				SEP 25, 2000	> ADD >		
			10MG;6.25MG	N75768 003	> ADD >	AB	
				SEP 25, 2000	> ADD >		
		PUREPAC PHARM	2.5MG;6.25MG	N75672 001	> ADD >	AB	
				SEP 25, 2000	> ADD >		
			5MG;6.25MG	N75672 002	> ADD >	AB	
				SEP 25, 2000	> ADD >		
			10MG;6.25MG	N75672 003	> ADD >	AB	
				SEP 25, 2000	> ADD >		
		ZENITH GOLDLINE	2.5MG;6.25MG	N75632 001	> ADD >	AB	
				SEP 27, 2000	> ADD >		
			5MG;6.25MG	N75632 002	> ADD >	AB	
				SEP 27, 2000	> ADD >		
			10MG;6.25MG	N75632 003	> ADD >	AB	
				SEP 27, 2000	> ADD >		
		ZIAC					
		LEDERLE	2.5MG;6.25MG	N20186 003	> ADD >	AB	
				MAR 26, 1993	> ADD >		
			5MG;6.25MG	N20186 001	> ADD >	AB	
				MAR 26, 1993	> ADD >		
			10MG;6.25MG	N20186 002	> ADD >	AB	+
				MAR 26, 1993	> ADD >		
			2.5MG;6.25MG	N20186 003	> DLT >		
				MAR 26, 1993	> DLT >		

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ZIAC

> DLT >		LEDERLE	5MG;6.25MG	N20186 001 MAR 26, 1993
> DLT >	+		10MG;6.25MG	N20186 002 MAR 26, 1993

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN

AP		FAULDING	EQ 15 UNITS BASE/VIAL	N65031 001 MAR 10, 2000
AP			EQ 30 UNITS BASE/VIAL	N65031 002 MAR 10, 2000
AP		GENSIA SICOR PHARMS	EQ 15 UNITS BASE/VIAL	N65033 001 JUN 27, 2000
AP			EQ 30 UNITS BASE/VIAL	N65033 002 JUN 27, 2000

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

AP		ASTRAZENECA	50MG/ML	N71151 001 AUG 10, 1987
	@		50MG/ML	N71151 001 AUG 10, 1987

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

DIMETANE-DC

AA	+	ROBINS AH	2MG/5ML;10MG/5ML; 12.5MG/5ML	N11694 006 MAR 29, 1984
	@		2MG/5ML;10MG/5ML; 12.5MG/5ML	N11694 006 MAR 29, 1984

MYPHETANE DC

AA		MORTON GROVE	2MG/5ML;10MG/5ML; 12.5MG/5ML	N88904 001 FEB 21, 1985

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

MYPHETANE DC

AA	+	MORTON GROVE	2MG/5ML;10MG/5ML; 12.5MG/5ML	N88904 001 FEB 21, 1985

BUDESONIDE

SUSPENSION; INHALATION

PULMICORT RESPULES

	ASTRAZENECA PHARMS	0.25MG/2ML	N20929 001 AUG 08, 2000
+		0.5MG/2ML	N20929 002 AUG 08, 2000
@		1MG/2ML	N20929 003 AUG 08, 2000

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HCL

AB	INVAMED	75MG	N75584 001 FEB 07, 2000
AB		100MG	N75584 002 FEB 07, 2000
AB	MYLAN	75MG	N75491 001 APR 17, 2000
AB		100MG	N75491 002 APR 17, 2000

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

+	BRISTOL MYERS SQUIBB	15MG	N18731 003 APR 22, 1996
@		30MG	N18731 004 APR 22, 1996
		15MG	N18731 003 APR 22, 1996
+		30MG	N18731 004 APR 22, 1996

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
BUTORPHANOL TARTRATE

AP	ABBOTT	1MG/ML	N75559 001	MAR 20, 2000
AP		2MG/ML	N75559 002	MAR 20, 2000

CALCIUM CHLORIDE

INJECTABLE; INJECTION
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

+	ABBOTT	100MG/ML	N21117 001	JAN 28, 2000

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC
CARDIOPLEGIC IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML	N75323 001	APR 21, 2000

PLEGISOL IN PLASTIC CONTAINER

AT	+ ABBOTT	17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML	N18608 001	FEB 26, 1982
	+	17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML	N18608 001	FEB 26, 1982

> ADD > CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

> ADD > TABLET; ORAL
> ADD > ATACAND HCT

> ADD >	ASTRAZENECA	16MG;12.5MG	N21093 001	SEP 05, 2000
> ADD >	+	32MG;12.5MG	N21093 002	SEP 05, 2000

CANDICIDIN

OINTMENT; VAGINAL
VANOBID

@	AVENTIS PHARMS	0.6MG/GM	N61596 001

CANDICIDIN

OINTMENT; VAGINAL
VANOBID

+	HOECHST MARION RSSL	0.6MG/GM	N61596 001

TABLET; VAGINAL
VANOBID

@	AVENTIS PHARMS	3MG	N61613 001
+	HOECHST MARION RSSL	3MG	N61613 001

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB	DANBURY PHARMA	50MG;25MG	N74832 001	DEC 29, 1997
	@	50MG;25MG	N74832 001	DEC 29, 1997

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL
CARBIDOPA AND LEVODOPA

AB	MYLAN	25MG;100MG	N75091 002	APR 21, 2000

SINEMET CR

AB	DUPONT PHARMS	25MG;100MG	N19856 002	DEC 24, 1992
		25MG;100MG	N19856 002	DEC 24, 1992

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

> ADD > AA	COREPHARMA	350MG	N40397 001	SEP 21, 2000

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
CARTEOLOL HCL

AT	ALCON	1%	N75476 001	JAN 03, 2000

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	CARTEOLOL HCL				
AT	BAUSCH AND LOMB	1%	N75546 001		
			JAN 20, 2000		
	OCUPRESS				
AT	+ CIBA	1%	N19972 001		
			MAY 23, 1990		
	+	1%	N19972 001		
			MAY 23, 1990		

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	CEFAZOLIN AND DEXTROSE				
	+ B BRAUN	EQ 500MG BASE/VIAL	N50779 001		
			JUL 27, 2000		
	+	EQ 1GM BASE/VIAL	N50779 002		
			JUL 27, 2000		
	CEFAZOLIN SODIUM				
AP	AM PHARM PARTNERS	EQ 1MG BASE/VIAL	N64169 002		
			AUG 14, 1998		
AP		EQ 1GM BASE/VIAL	N64169 002		
			AUG 14, 1998		

CEFDINIR

CAPSULE; ORAL

	OMNICEF				
	+ ABBOTT	300MG	N50739 001		
			DEC 04, 1997		
	+ PARKE DAVIS	300MG	N50739 001		
			DEC 04, 1997		

POWDER FOR RECONSTITUTION; ORAL

	OMNICEF			> ADD >	
	+ ABBOTT	125MG/5ML	N50749 001	> ADD >	
			DEC 04, 1997	> ADD >	
	+ PARKE DAVIS	125MG/5ML	N50749 001	> ADD >	
			DEC 04, 1997	> ADD >	

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

	CEFOTAXIME		
AP	AM PHARM PARTNERS	EQ 500MG BASE/VIAL	N64200 001
			MAR 24, 2000
AP		EQ 1GM BASE/VIAL	N64200 002
			MAR 24, 2000
AP		EQ 2GM BASE/VIAL	N64200 003
			MAR 24, 2000
AP		EQ 10GM BASE/VIAL	N64201 001
			MAR 24, 2000
	+	EQ 20GM BASE/VIAL	N64201 002
			MAR 24, 2000
	CLAFORAN		
AP	+ AVENTIS PHARMS	EQ 500MG BASE/VIAL	N50547 001
AP	+	EQ 1GM BASE/VIAL	N50547 002
AP	+	EQ 2GM BASE/VIAL	N50547 003
AP	+	EQ 10GM BASE/VIAL	N50547 004
			DEC 29, 1983
	+ HOECHST MARION RSSL	EQ 500MG BASE/VIAL	N50547 001
	+	EQ 1GM BASE/VIAL	N50547 002
	+	EQ 2GM BASE/VIAL	N50547 003
	+	EQ 10GM BASE/VIAL	N50547 004
			DEC 29, 1983

CEFOXITIN SODIUM

INJECTABLE; INJECTION

	CEFOXITIN		
AP	AM PHARM PARTNERS	EQ 1GM BASE/VIAL	N65012 001
			JUL 03, 2000
AP		EQ 2GM BASE/2VIAL	N65012 002
			JUL 03, 2000
AP		EQ 10GM BASE/VIAL	N65011 001
			JUL 03, 2000
AP	ESI LEDERLE	EQ 1GM BASE/VIAL	N65051 001
			SEP 11, 2000
AP		EQ 2GM BASE/VIAL	N65051 002
			SEP 11, 2000
AP		EQ 10GM BASE/VIAL	N65050 001
			SEP 11, 2000
	MEFOXIN		
AP	+ MERCK	EQ 1GM BASE/VIAL	N50517 001
AP		EQ 1GM BASE/VIAL	N62757 001
			JAN 08, 1987
AP	+	EQ 2GM BASE/VIAL	N50517 002

CEFOXITIN SODIUM

INJECTABLE; INJECTION
MEFOXIN

AP		MERCK	EQ 2GM BASE/VIAL	N62757 002 JAN 08, 1987
AP	+		EQ 10GM BASE/VIAL	N50517 003
	*		EQ 1GM BASE/VIAL	N50517 001
			EQ 1GM BASE/VIAL	N62757 001 JAN 08, 1987
	*		EQ 2GM BASE/VIAL	N50517 002
			EQ 2GM BASE/VIAL	N62757 002 JAN 08, 1987
	*		EQ 10GM BASE/VIAL	N50517 003

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL
CEDAX

+	DJ PHARMA	EQ 400MG BASE	N50685 002 DEC 20, 1995
*	SCHERING PLOUGH	EQ 400MG BASE	N50685 002 DEC 20, 1995

POWDER FOR RECONSTITUTION; ORAL
CEDAX

	DJ PHARMA	EQ 90MG BASE/5ML	N50686 001 DEC 20, 1995
+		EQ 180MG BASE/5ML	N50686 002 DEC 20, 1995
*	SCHERING PLOUGH	EQ 90MG BASE/5ML	N50686 001 DEC 20, 1995
*		EQ 180MG BASE/5ML	N50686 002 DEC 20, 1995

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN

+	HLR	EQ 250MG BASE/VIAL	N50585 001 DEC 21, 1984
		EQ 250MG BASE/VIAL	N63239 001 AUG 13, 1993
+		EQ 500MG BASE/VIAL	N50585 002 DEC 21, 1984
		EQ 500MG BASE/VIAL	N63239 002 AUG 13, 1993

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN

+	HLR	EQ 1GM BASE/VIAL	N50585 003 DEC 21, 1984
		EQ 1GM BASE/VIAL	N62654 002 APR 30, 1987
		EQ 1GM BASE/VIAL	N63239 003 AUG 13, 1993
+		EQ 2GM BASE/VIAL	N50585 004 DEC 21, 1984
		EQ 2GM BASE/VIAL	N62654 003 APR 30, 1987
+		EQ 10GM BASE/VIAL	N50585 005 DEC 21, 1984
*	ROCHE	EQ 250MG BASE/VIAL	N50585 001 DEC 21, 1984
		EQ 250MG BASE/VIAL	N63239 001 AUG 13, 1993
*		EQ 500MG BASE/VIAL	N50585 002 DEC 21, 1984
		EQ 500MG BASE/VIAL	N63239 002 AUG 13, 1993
*		EQ 1GM BASE/VIAL	N50585 003 DEC 21, 1984
		EQ 1GM BASE/VIAL	N62654 002 APR 30, 1987
		EQ 1GM BASE/VIAL	N63239 003 AUG 13, 1993
*		EQ 2GM BASE/VIAL	N50585 004 DEC 21, 1984
		EQ 2GM BASE/VIAL	N62654 003 APR 30, 1987
*		EQ 10GM BASE/VIAL	N50585 005 DEC 21, 1984

ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

@	HLR	EQ 10MG BASE/ML	N50624 001 FEB 11, 1987
+		EQ 20MG BASE/ML	N50624 002 FEB 11, 1987
+		EQ 40MG BASE/ML	N50624 003 FEB 11, 1987
@	ROCHE	EQ 10MG BASE/ML	N50624 001 FEB 11, 1987
*		EQ 20MG BASE/ML	N50624 002 FEB 11, 1987
*		EQ 40MG BASE/ML	N50624 003 FEB 11, 1987

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE; INJECTION
ROCEPHIN KIT

	+	HLR	EQ 1GM BASE/VIAL,N/A;N/A, 1%	N50585 006 MAY 08, 1996	>DLT> >DLT>
	+		EQ 500MG BASE/VIAL,N/A;N/A, 1%	N50585 007 MAY 08, 1996	>ADD> >ADD> >ADD> >ADD>
	*	ROCHE	EQ 1GM BASE/VIAL,N/A;N/A, 1%	N50585 006 MAY 08, 1996	
	*		EQ 500MG BASE/VIAL,N/A;N/A, 1%	N50585 007 MAY 08, 1996	

CEPHALEXIN

POWDER FOR RECONSTITUTION; ORAL
KEFLEX

AB	*	LILLY	EQ 125MG BASE/5ML	N50406 001
AB	*		EQ 250MG BASE/5ML	N50406 002
AB			EQ 250MG BASE/5ML	N62117 003
AB	+		EQ 250MG BASE/5ML	N62117 003
	@		EQ 125MG BASE/5ML	N50406 001
	@		EQ 250MG BASE/5ML	N50406 002

CERIVASTATIN SODIUM

TABLET; ORAL
BAYCOL

	+	BAYER	0.4MG	N20740 005 MAY 24, 1999
			0.4MG	N20740 005 MAY 24, 1999
	+		0.8MG	N20740 006 JUL 24, 2000

CETRORELIX

INJECTABLE; INJECTION
CETROTIDE

>DLT>	*	ASTA	EQ 0.25MG BASE/ML	N21197 001 AUG 11, 2000	
>DLT>					

CETRORELIX

INJECTABLE; INJECTION
CETROTIDE

*	ASTA	EQ 3MG BASE/ML	N21197 002 AUG 11, 2000	
+	SERONO INC	EQ 0.25MG BASE/ML	N21197 001 AUG 11, 2000	
+		EQ 3MG BASE/ML	N21197 002 AUG 11, 2000	

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL
EVOXAC

+	SNOWBRAND	EQ 30MG BASE	N20989 002 JAN 11, 2000

CHENODIOL

TABLET; ORAL
CHENIX

@	AXCAN	250MG	N18513 002 JUL 28, 1983
@	AXCAN SCANDIPHARM	250MG	N18513 002 JUL 28, 1983

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
CHLORPHENIRAMINE MALEATE

AA	GLOBAL PHARM	4MG	N80809 001
@	IMPAX LABS	4MG	N80809 001

CICLOPIROX

CREAM; TOPICAL
LOPROX

+	AVENTIS PHARMS	0.77%	N18748 001 DEC 30, 1982

LOTION; TOPICAL
LOPROX

+	AVENTIS PHARMS	0.77%	N19824 001 DEC 30, 1988

CICLOPIROX OLAMINE

CREAM; TOPICAL
LOPROX
* HOECHST MARION RSSL 1% N18748 001 DEC 30, 1982

LOTION; TOPICAL
LOPROX
* HOECHST MARION RSSL 1% N19824 001 DEC 30, 1988

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL
CIMETIDINE HCL
AA NOVEX EQ 300MG BASE/5ML N75560 001 MAR 15, 2000 > ADD > > ADD >

CISAPRIDE MONOHYDRATE

SUSPENSION; ORAL
PROPULSID
* JANSSEN EQ 1MG BASE/ML N20398 001 SEP 15, 1995
@ EQ 1MG BASE/ML N20398 001 SEP 15, 1995

TABLET; ORAL
PROPULSID
JANSSEN EQ 10MG BASE N20210 001 JUL 29, 1993
* EQ 20MG BASE N20210 002 DEC 23, 1993
@ EQ 10MG BASE N20210 001 JUL 29, 1993
@ EQ 20MG BASE N20210 002 DEC 23, 1993

CISPLATIN

INJECTABLE; INJECTION
CISPLATIN
AP GENSIA SICOR PHARMS 1MG/ML N74814 001 MAY 16, 2000

CISPLATIN

INJECTABLE; INJECTION
CISPLATIN
AP PHARMACHEMIE 1MG/ML N74656 001 MAY 16, 2000

CITALOPRAM HYDROBROMIDE

TABLET; ORAL
CELEXA
FOREST LABS EQ 40MG BASE N20822 003 JUL 17, 1998
* EQ 60MG BASE N20822 004 JUL 17, 1998
EQ 10MG BASE N20822 001 APR 27, 2000
\+ EQ 40MG BASE N20822 003 JUL 17, 1998
@ EQ 60MG BASE N20822 004 JUL 17, 1998

CLADRIBINE

INJECTABLE; INJECTION
CLADRIBINE
AP BEDFORD 1MG/ML N75405 001 FEB 28, 2000

CLARITHROMYCIN

TABLET; ORAL
BIAXIN
ABBOTT 250MG N50662 001 OCT 31, 1991
\+ 250MG N50662 001 OCT 31, 1991

TABLET, EXTENDED RELEASE; ORAL
BIAXIN XL
\+ ABBOTT 500MG N50775 001 MAR 03, 2000

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL
CLEOCIN T
AB + PHARMACIA AND UPJOHN EQ 1% BASE N50615 001 JAN 07, 1987
+ EQ 1% BASE N50615 001 JAN 07, 1987
CLINDAMYCIN PHOSPHATE
AB ALTANA EQ 1% BASE N64160 001 JAN 28, 2000

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE
AT CLAY PARK EQ 1% BASE N65049 001 MAY 25, 2000

CLOBETASOL PROPIONATE

AEROSOL; TOPICAL
OLUX FOAM
+ CONNETICS 0.05% N21142 001 MAY 26, 2000

CREAM; TOPICAL
CLOBETASOL PROPIONATE
AB2 TARO 0.05% N75633 001 MAY 17, 2000

GEL; TOPICAL
CLOBETASOL PROPIONATE
AB ALTANA 0.05% N75368 001 FEB 15, 2000

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM
AB TARO 3.75MG N75731 003 APR 27, 2000
AB 7.5MG N75731 002 APR 27, 2000
AB 15MG N75731 001 APR 27, 2000

CLOTRIMAZOLE

TABLET, VAGINAL
MYCELEX-G
+ BAYER 500MG N19069 001 APR 19, 1985
@ 500MG N19069 001 APR 19, 1985

CLOXACILLIN SODIUM

CAPSULE; ORAL
CLOXACILLIN SODIUM
AB + APOTHECON EQ 250MG BASE N61452 001
AB + EQ 500MG BASE N61452 002
@ EQ 250MG BASE N61452 001
@ EQ 500MG BASE N61452 002
CLOXAPEN
AB SMITHKLINE BEECHAM EQ 500MG BASE N61806 002
AB + EQ 500MG BASE N61806 002

COLESEVELAM HYDROCHLORIDE

CAPSULE; ORAL
WELCHOL
+ GELTEX 375MG N21141 001 MAY 26, 2000
+ SANKYO PHARMA INC 375MG N21141 001 MAY 26, 2000

TABLET; ORAL
WELCHOL
+ GELTEX 625MG N21176 001 MAY 26, 2000
+ SANKYO PHARMA INC 625MG N21176 001 MAY 26, 2000

CORTISONE ACETATE

TABLET; ORAL
CORTISONE ACETATE
BP GLOBAL PHARM 25MG N09458 001
@ IMPAX LABS 25MG N09458 001

CROMOLYN SODIUM

CONCENTRATE; ORAL
GASTROCROM
+ MEDEVA 100MG/5ML N20479 001 FEB 29, 1996

SOLUTION; INHALATION
CROMOLYN SODIUM
AN STERIPAK 10MG/ML N75271 001 JAN 18, 2000
AN WARRICK PHARMS 10MG/ML N75437 001 APR 21, 2000

SOLUTION, CONCENTRATE; ORAL
GASTROCROM
+ MEDEVA 100MG/5ML N20479 001 FEB 29, 1996

CYANOCOBALAMIN

INJECTABLE; INJECTION
CYANOCOBALAMIN
@ AVENTIS PHARMS 1MG/ML N80564 001
AP HOECHST MARION RSSL 1MG/ML N80564 001

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
CYCLOPENTOLATE HCL
AT ALCON UNIVERSAL 1% N89162 001 JAN 24, 1991
AT STERIS 1% N89162 001 JAN 24, 1991

CYCLOSPORINE

CAPSULE; ORAL
CYCLOSPORINE
AB ABBOTT 25MG N65003 001 MAY 12, 2000
AB 50MG N65003 002 MAY 12, 2000
AB 100MG N65003 003 MAY 12, 2000

CYCLOSPORINE

CAPSULE; ORAL
CYCLOSPORINE
AB EON 25MG N65017 002 JAN 13, 2000
AB 100MG N65017 001 JAN 13, 2000

NEORAL
AB NOVARTIS 25MG N50715 001 JUL 14, 1995
AB 50MG N50715 003 JUL 14, 1995
AB + 100MG N50715 002 JUL 14, 1995
BX 25MG N50715 001 JUL 14, 1995
BX 50MG N50715 003 JUL 14, 1995
BX + 100MG N50715 002 JUL 14, 1995

SOLUTION; ORAL
CYCLOSPORINE
AB ABBOTT 100MG/ML N65025 001 MAR 03, 2000

SANGCYA
AB SANGSTAT MEDCL 100MG/ML N64195 001 OCT 31, 1998
@ 100MG/ML N64195 001 OCT 31, 1998

DACARBAZINE

INJECTABLE; INJECTION
DACARBAZINE
>ADD> AP GENSIA SICOR PHARMS 500MG/VIAL N75259 001 SEP 22, 2000
>ADD>

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION
DAUNOXOME
+ GILEAD EQ 2MG BASE/ML N50704 002 APR 08, 1996
* NEXSTAR EQ 2MG BASE/ML N50704 002 APR 08, 1996

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DAUNORUBICIN HCL

AP	+	BEDFORD	EQ 5MG BASE/ML	N50731 001 JAN 30, 1998
	*		EQ 5MG BASE/ML	N50731 001 JAN 30, 1998
AP		GENSIA SICOR PHARMS	EQ 5MG BASE/ML	N65035 001 JAN 24, 2000
	+		EQ 50MG BASE/VIAL	N64212 002 MAY 03, 1999

DEMECLOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
DECLOMYCIN

*	LEDERLE	150MG	N50262 001
@		150MG	N50262 001

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
DESMOPRESSIN ACETATE

AP	ABBOTT	0.004MG/ML	N75220 001 AUG 28, 2000
AP	BEDFORD	0.004MG/ML	N74575 001 FEB 18, 2000

DESMOPRESSIN ACETATE PRESERVATIVE FREE

AP	BEDFORD	0.004MG/ML	N74574 001 FEB 18, 2000

SPRAY, METERED; NASAL
STIMATE

+	AVENTIS BEHRING	0.15MG/SPRAY	N20355 001 MAR 07, 1994
*	CENTEON	0.15MG/SPRAY	N20355 001 MAR 07, 1994

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
MIRCETTE

*	ORGANON	0.15MG;0.02MG	N20713 001 APR 22, 1998

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
MIRCETTE

+	ORGANON	0.15MG,N/A;0.02MG,0.01MG	N20713 001 APR 22, 1998

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT	ALCON UNIVERSAL	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62721 001 NOV 17, 1986
AT	STERIS	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62721 001 NOV 17, 1986

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS, OPHTHALMIC, OTIC
DEXAMETHASONE SODIUM PHOSPHATE

AT	ALCON UNIVERSAL	EQ 0.1% PHOSPHATE	N88771 001 JAN 16, 1985

SOLUTION/DROPS; OPHTHALMIC, OTIC
DEXAMETHASONE SODIUM PHOSPHATE

AT	STERIS	EQ 0.1% PHOSPHATE	N88771 001 JAN 16, 1985

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

AT	ALCON UNIVERSAL	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	N62714 001 JUL 21, 1986
AT	STERIS	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	N62714 001 JUL 21, 1986

DEZOCINE

INJECTABLE; INJECTION
DALGAN

*	ASTRAZENECA	5MG/ML	N19082 001 DEC 29, 1989
*		10MG/ML	N19082 002 DEC 29, 1989
*		15MG/ML	N19082 003 DEC 29, 1989
@		5MG/ML	N19082 001 DEC 29, 1989
@		10MG/ML	N19082 002 DEC 29, 1989
@		15MG/ML	N19082 003 DEC 29, 1989

DIAZEPAM

INJECTABLE; INJECTION
DIZAC

@	PHARMACIA AND UPJOHN	5MG/ML	N19287 001 JUN 18, 1993

INJECTABLE; INTRAVENOUS
DIZAC

*	PHARMACIA AND UPJOHN	5MG/ML	N19287 001 JUN 18, 1993

DICLOFENAC POTASSIUM

TABLET; ORAL
DICLOFENAC POTASSIUM

AB	GENEVA PHARMS TECH	50MG	N75229 001 NOV 20, 1998
AB	INVAMED	50MG	N75229 001 NOV 20, 1998

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
DICLOFENAC SODIUM †

AB	FALCON PHARMS	0.1%	N20809 001 MAY 04, 1998
@		0.1%	N20809 001 MAY 04, 1998

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
VOLTAREN

AB	* CIBA	0.1%	N20037 001 MAR 28, 1991
+		0.1%	N20037 001 MAR 28, 1991

TABLET, EXTENDED RELEASE; ORAL
DICLOFENAC SODIUM

AB	BIOVAIL	100MG	N75492 001 FEB 11, 2000

VOLTAREN-XR

AB	+ NOVARTIS	100MG	N20254 001 MAR 08, 1996
*		100MG	N20254 001 MAR 08, 1996

DIENESTROL

SUPPOSITORY; VAGINAL
DV

@	AVENTIS PHARMS	0.7MG	N83517 001
*	HOECHST MARION RSSL	0.7MG	N83517 001

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL
DIETHYLPROPION HCL

AA	MD PHARM	25MG	N85544 001
@	MEDEVA PHARMS CA	25MG	N85544 001

DIETHYLSTILBESTROL DIPHOSPHATE

> DLT >
INJECTABLE; INJECTION
STILPHOSTROL

*	BAYER	250MG/5ML	N10010 001
@		250MG/5ML	N10010 001

> DLT >
TABLET; ORAL
STILPHOSTROL

*	BAYER	50MG	N10010 002
@		50MG	N10010 002

† SEE SECTION 1.3 OF INTRODUCTION

DIFLORASONE DIACETATE

CREAM; TOPICAL
DIFLORASONE DIACETATE

AB	TARO	0.05%	N75508 001 APR 24, 2000

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HCL

AB3	BIOVAIL	120MG	N20939 001 JAN 28, 2000
AB3		180MG	N20939 002 JAN 28, 2000
AB3		240MG	N20939 003 JAN 28, 2000
AB3		300MG	N20939 004 JAN 28, 2000

INJECTABLE; INJECTION
DILTIAZEM HCL

AP	ABBOTT	5MG/ML	N75004 001 FEB 16, 2000

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL
TIAMATE

+	HOECHST MARION RSSL	EQ 120MG HCL	N20506 001 OCT 04, 1996
+		EQ 180MG HCL	N20506 002 OCT 04, 1996
+		EQ 240MG HCL	N20506 003 OCT 04, 1996
+	MERCK	EQ 120MG HCL	N20506 001 OCT 04, 1996
+		EQ 180MG HCL	N20506 002 OCT 04, 1996
+		EQ 240MG HCL	N20506 003 OCT 04, 1996

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

AA	GLOBAL PHARM	25MG	N80807 001

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

AA	GLOBAL PHARM	50MG	N80807 002
	IMPAX LABS	25MG	N80807 001
	@	50MG	N80807 002

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL
DEPAKOTE ER

+	ABBOTT	EQ 500MG VALPROIC ACID	N21168 001 AUG 04, 2000

DOXEPIN HYDROCHLORIDE

CREAM; TOPICAL
ZONALON

+	BIOGLAN PHAR	5%	N20126 001 APR 01, 1994
+	MEDICIS	5%	N20126 001 APR 01, 1994

DOXERCALCIFEROL

INJECTABLE; INJECTION
HECTOROL

+	BONE CARE	2 UGM/ML	N21027 001 APR 06, 2000

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

AB	EON	EQ 50MG BASE	N65032 001 JUN 30, 2000
AB		EQ 100MG BASE	N65032 002 JUN 30, 2000
AB	HALSEY	EQ 50MG BASE	N65041 001 APR 28, 2000
AB		EQ 100MG BASE	N65041 002 APR 28, 2000
	MONODOX		
AB	OCLASSEN	EQ 50MG BASE	N50641 002 FEB 10, 1992

DOXYCYCLINE

CAPSULE; ORAL

		MONODOX		
AB	+	OCLASSEN	EQ 100MG BASE	N50641 001 DEC 29, 1989
			EQ 50MG BASE	N50641 002 FEB 10, 1992
	*		EQ 100MG BASE	N50641 001 DEC 29, 1989

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL

		VANIQA		
	+	WESTWOOD SQUIBB CLTN	13.9%	N21145 001 JUL 27, 2000

ENALAPRIL MALEATE

TABLET; ORAL

		ENALAPRIL MALEATE		
AB		APOTHECON	2.5MG	N75583 001 AUG 22, 2000
AB			5MG	N75583 002 AUG 22, 2000
AB			10MG	N75583 003 AUG 22, 2000
AB			20MG	N75583 004 AUG 22, 2000
AB		CHELSEA LABS	2.5MG	N75501 001 AUG 22, 2000
AB			5MG	N75501 002 AUG 22, 2000
AB			10MG	N75501 003 AUG 22, 2000
AB			20MG	N75501 004 AUG 22, 2000
AB		EON	2.5MG	N75621 001 AUG 22, 2000
AB			5MG	N75621 002 AUG 22, 2000
AB			10MG	N75621 003 AUG 22, 2000
AB			20MG	N75621 004 AUG 22, 2000

ENALAPRIL MALEATE

TABLET; ORAL

		ENALAPRIL MALEATE		
AB		GENEVA PHARMS	2.5MG	N75048 001 AUG 22, 2000
AB			5MG	N75048 002 AUG 22, 2000
AB			10MG	N75048 003 AUG 22, 2000
AB			20MG	N75048 004 AUG 22, 2000
AB		GENPHARM	2.5MG	N75472 001 AUG 22, 2000
AB			5MG	N75472 002 AUG 22, 2000
AB			10MG	N75472 003 AUG 22, 2000
AB			20MG	N75472 004 AUG 22, 2000
AB		KRKA DD NOVO MESTO	2.5MG	N75370 001 AUG 22, 2000
AB			5MG	N75370 002 AUG 22, 2000
AB			10MG	N75369 001 AUG 22, 2000
AB			20MG	N75369 002 AUG 22, 2000
AB		LEK PHARM	2.5MG	N75496 001 AUG 22, 2000
AB			5MG	N75496 002 AUG 22, 2000
AB			10MG	N75459 001 AUG 22, 2000
AB			20MG	N75459 002 AUG 22, 2000
AB		MYLAN	2.5MG	N75480 001 AUG 22, 2000
AB			5MG	N75480 002 AUG 22, 2000
AB			10MG	N75480 003 AUG 22, 2000
AB			20MG	N75480 004 AUG 22, 2000
AB		RANBAXY	2.5MG	N75556 001 AUG 22, 2000
AB			5MG	N75556 002 AUG 22, 2000

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

AB		RANBAXY	10MG	N75556 003 AUG 22, 2000
AB			20MG	N75556 004 AUG 22, 2000
AB		TEVA	2.5MG	N75479 001 AUG 22, 2000
AB			5MG	N75479 002 AUG 22, 2000
AB			10MG	N75479 003 AUG 22, 2000
AB			20MG	N75479 004 AUG 22, 2000
AB		WOCKHARDT	2.5MG	N75483 001 AUG 22, 2000
AB			5MG	N75483 002 AUG 22, 2000
AB			10MG	N75483 003 AUG 22, 2000
AB			20MG	N75483 004 AUG 22, 2000
AB		ZENITH GOLDLINE	2.5MG	N75482 001 AUG 22, 2000
AB			5MG	N75482 002 AUG 22, 2000
AB			10MG	N75482 003 AUG 22, 2000
AB			20MG	N75482 004 AUG 22, 2000

VASOTEC

AB		MERCK	2.5MG	N18998 005 JUL 26, 1988
AB			5MG	N18998 001 DEC 24, 1985
AB			10MG	N18998 002 DEC 24, 1985
AB	+		20MG	N18998 003 DEC 24, 1985
			2.5MG	N18998 005 JUL 26, 1988
			5MG	N18998 001 DEC 24, 1985
			10MG	N18998 002 DEC 24, 1985
	*		20MG	N18998 003 DEC 24, 1985

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP		ABBOTT	1.25MG/ML	N75456 001 AUG 22, 2000
AP			1.25MG/ML	N75458 001 AUG 22, 2000
AP		BEDFORD	1.25MG/ML	N75634 001 AUG 22, 2000
AP		FAULDING	1.25MG/ML	N75571 001 AUG 22, 2000
AP		GENSIA SICOR PHARMS	1.25MG/ML	N75578 001 AUG 22, 2000

VASOTEC

AP	+	MERCK	1.25MG/ML	N19309 001 FEB 09, 1988
	*		1.25MG/ML	N19309 001 FEB 09, 1988

ENFLURANE

LIQUID; INHALATION

ETHRANE

AN	+	BAXTER PHARM PROD	99.9%	N17087 001
AN	*	OHMEDA	99.9%	N17087 001

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

ERGOMAR

AA		LOTUS BIOCHEM	2MG	N87693 001 FEB 24, 1983
	+		2MG	N87693 001 FEB 24, 1983

ERGOSTAT

AA		PARKE DAVIS	2MG	N88337 001 JUN 08, 1984
	@		2MG	N88337 001 JUN 08, 1984

WIGRETTES

AA	+	ORGANON	2MG	N86750 001 JUL 29, 1982
	@		2MG	N86750 001 JUL 29, 1982

ERYTHROMYCIN

SOLUTION; TOPICAL

SANSAC

AT		GALDERMA LABS	2%	N62522 001 JAN 24, 1985
AT		HEALTHPOINT	2%	N62522 001 JAN 24, 1985

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

PEDIAMYCIN

AB		ROSS LABS	EQ 200MG BASE/5ML	N62305 001
	@		EQ 200MG BASE/5ML	N62305 001

SUSPENSION/DROPS; ORAL

PEDIAMYCIN

	+	ROSS LABS	EQ 100MG BASE/2.5ML	N62305 002
	@		EQ 100MG BASE/2.5ML	N62305 002

TABLET, CHEWABLE; ORAL

PEDIAMYCIN

AB		ROSS LABS	EQ 200MG BASE	N62306 001
	@		EQ 200MG BASE	N62306 001

ESTRADIOL

CREAM; VAGINAL

ESTRACE

	+	BRISTOL MYERS SQUIBB	0.01%	N86069 001 JAN 31, 1984
	+	WARNER CHILCOTT	0.01%	N86069 001 JAN 31, 1984

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA

AB	+	BERLEX LABS	0.05MG/24HR	N20375 001 DEC 22, 1994
AB	+		0.1MG/24HR	N20375 002 DEC 22, 1994
BX	+		0.05MG/24HR	N20375 001 DEC 22, 1994
BX	+		0.1MG/24HR	N20375 002 DEC 22, 1994

ESTRADIOL

BX		CYGNUS CA	0.05MG/24HR	N21048 001 SEP 20, 1999

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ESTRADIOL

BX		CYGNUS CA	0.075MG/24HR	N21048 002 SEP 20, 1999
BX			0.1MG/24HR	N21048 003 SEP 20, 1999
	@	JOHNSON RW	0.05MG/24HR	N21048 001 SEP 20, 1999
	@		0.075MG/24HR	N21048 002 SEP 20, 1999
	@		0.1MG/24HR	N21048 003 SEP 20, 1999
AB		MYLAN TECHNOLOGIES	0.05MG/24HR	N75233 001 FEB 24, 2000
AB			0.1MG/24HR	N75182 001 FEB 24, 2000

VIVELLE

	+	NOVARTIS	0.025MG/24HR	N20323 005 AUG 16, 2000

TABLET; ORAL

ESTRADIOL

AB		APPLIED ANAL	0.5MG	N40138 001 JAN 30, 1998
AB			1MG	N40138 002 JAN 30, 1998
AB			2MG	N40138 003 JAN 30, 1998
AB		ENDEAVOR	0.5MG	N40138 001 JAN 30, 1998
AB			1MG	N40138 002 JAN 30, 1998
AB			2MG	N40138 003 JAN 30, 1998

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

ETHAMOLIN

	+	CYPROS	50MG/ML	N19357 001 DEC 22, 1988
	+	QUESTCOR PHARM	50MG/ML	N19357 001 DEC 22, 1988

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21
TRIVORA-21
AB SEARLE 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG N74538 001 DEC 18, 1997
AB WATSON LABS 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG N74538 001 DEC 18, 1997

TABLET; ORAL-28
TRIVORA-28
AB SEARLE 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG N74538 002 DEC 18, 1997
AB WATSON LABS 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG N74538 002 DEC 18, 1997

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
OVCON-35
+ BRISTOL MYERS SQUIBB 0.035MG;0.4MG N18127 001
+ WARNER CHILCOTT 0.035MG;0.4MG N18127 001
OVCON-50
@ BRISTOL MYERS SQUIBB 0.05MG;1MG N18128 001
@ WARNER CHILCOTT 0.05MG;1MG N18128 001

TABLET; ORAL-28
OVCON-35
BRISTOL MYERS SQUIBB 0.035MG;0.4MG N17716 001
WARNER CHILCOTT 0.035MG;0.4MG N17716 001
OVCON-50
BRISTOL MYERS SQUIBB 0.05MG;1MG N17576 001
WARNER CHILCOTT 0.05MG;1MG N17576 001

ETODOLAC

CAPSULE; ORAL
ETODOLAC
AB TORPHARM 200MG N75419 001 JUL 28, 2000
AB 300MG N75419 002 JUL 28, 2000

ETODOLAC

TABLET; ORAL
ETODOLAC
AB TARO PHARM INDS 500MG N75074 002 APR 25, 2000

TABLET, EXTENDED RELEASE; ORAL
ETODOLAC
AB TEVA 500MG N75665 002 JUL 31, 2000
AB 600MG N75665 001 JUL 31, 2000
AB WHITNEY PHARMS 400MG N75696 001 JUL 31, 2000

LODINE XL
AB + WYETH AYERST 400MG N20584 001 OCT 25, 1996
AB + 500MG N20584 003 JAN 20, 1998
AB + 600MG N20584 002 OCT 25, 1996
+ 400MG N20584 001 OCT 25, 1996
+ 500MG N20584 003 JAN 20, 1998
+ 600MG N20584 002 OCT 25, 1996

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION
CORLOPAM
+ ABBOTT EQ 10MG BASE/ML N19922 001 SEP 23, 1997
+ ELAN PHARMA EQ 10MG BASE/ML N19922 001 SEP 23, 1997

FENTANYL CITRATE

INJECTABLE; INJECTION
SUBLIMAZE PRESERVATIVE FREE
AP + AKORN MFG EQ 0.05MG BASE/ML N16619 001
AP + JANSSEN EQ 0.05MG BASE/ML N16619 001

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL
ALLEGRA
AVENTIS PHARMS — 30MG — N20872 001 FEB 25, 2000
60MG — N20872 002 FEB 25, 2000
+ 180MG — N20872 004 FEB 25, 2000

FLOXURIDINE

INJECTABLE; INJECTION
FLOXURIDINE
AP BEDFORD — **500MG/VIAL** — **N75387 001 APR 16, 2000**

FUDR
AP + ROCHE — **500MG/VIAL** — **N16929 001**
* 500MG/VIAL N16929 001

FLUCONAZOLE

TABLET; ORAL
DIFLUCAN
PFIZER — 150MG — N20322 001 JUN 30, 1994
150MG — N19949 004 JUN 30, 1994

FLUMAZENIL

INJECTABLE; INJECTION
ROMAZICON
+ HLR — 0.1MG/ML — N20073 001 DEC 20, 1991
* ROCHE — 0.1MG/ML — N20073 001 DEC 20, 1991

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL
AP GENSIA SICOR PHARMS — **50MG/ML** — **N40333 001 JAN 27, 2000**

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL
AP GENSIA SICOR PHARMS — **50MG/ML** — **N40334 001 FEB 25, 2000**

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
SARAFEM
LILLY — EQ 10MG BASE — N18936 007 JUL 06, 2000
+ EQ 20MG BASE — N18936 008 JUL 06, 2000

FLUTICASONE PROPIONATE

POWDER; INHALATION
FLOVENT DISKUS 100
+ GLAXO — 0.1MG/INH — N20833 002 SEP 29, 2000

FLOVENT DISKUS 250
+ GLAXO — 0.25MG/INH — N20833 003 SEP 29, 2000

FLOVENT DISKUS 50
+ GLAXO — 0.05MG/INH — N20833 001 SEP 29, 2000

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION
ADVAIR DISKUS 100/50
+ GLAXO WELLCOME — 0.1MG/INH; EQ 0.05MG BASE/INH — N21077 001 AUG 24, 2000

ADVAIR DISKUS 250/50
+ GLAXO WELLCOME — 0.25MG/INH; EQ 0.05MG BASE/INH — N21077 002 AUG 24, 2000

ADVAIR DISKUS 500/50
+ GLAXO WELLCOME — 0.5MG/INH; EQ 0.05MG BASE/INH — N21077 003 AUG 24, 2000

FOLLITROPIN ALFA/BETA

INJECTABLE; INJECTION

	GONAL-F			
>ADD>	SERONO	37.5 IU/VIAL	N20378 003	
>ADD>			MAY 25, 2000	

FURAZOLIDONE

SUSPENSION; ORAL

	FUROXONE		
+	ROBERTS LABS	50MG/15ML	N11323 002
+	SHIRE LABS	50MG/15ML	N11323 002

TABLET; ORAL

	FUROXONE		
+	ROBERTS LABS	100MG	N11270 002
+	SHIRE LABS	100MG	N11270 002

GABAPENTIN

SOLUTION; ORAL

	NEURONTIN		
+	PARKE DAVIS	250MG/5ML	N21129 001
			MAR 02, 2000

GADOPENTETATE DIMEGLUMINE

INJECTABLE; INJECTION

	MAGNEVIST		
+	BERLEX LABS	469.01MG/ML	N21037 001
			MAR 10, 2000

GEMTUZUMAB OZOGAMICIN

INJECTABLE; INJECTION

	MYLOTARG		
+	WYETH AYERST	5MG/VIAL	N21174 001
			MAY 17, 2000

GENTAMICIN SULFATE

INJECTABLE; INJECTION

	GARAMYCIN		
AP	@ SCHERING	EQ 10MG BASE/ML	N61739 001

GENTAMICIN SULFATE

INJECTABLE; INJECTION

	GARAMYCIN		
	@ SCHERING	EQ 10MG BASE/ML	N61739 001
	GENTAMICIN SULFATE		
AP	ELKINS SINN	EQ 10MG BASE/ML	N62251 002
AP	+	EQ 10MG BASE/ML	N62251 002

SOLUTION/DROPS; OPHTHALMIC

	GENTAMICIN SULFATE		
AT	ALCON UNIVERSAL	EQ 0.3% BASE	N62523 001
			NOV 25, 1985
AT	STERIS	EQ 0.3% BASE	N62523 001
			NOV 25, 1985

GLUTETHIMIDE

TABLET; ORAL

	GLUTETHIMIDE		
	@ MD PHARM	500MG	N85171 001
	@ MEDEVA PHARMS CA	500MG	N85171 001

GLYBURIDE

TABLET; ORAL

	GLYBURIDE (MICRONIZED)		
AB	AVENTIS PHARMS	6MG	N20055 003
			MAR 08, 2000

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

	GLUCOVANCE		
	BRISTOL MYERS SQUIBB	1.25MG;250MG	N21178 001
			JUL 31, 2000
		2.5MG;500MG	N21178 002
			JUL 31, 2000
+		5MG;500MG	N21178 003
			JUL 31, 2000

> ADD > GONADOTROPIN CHORIONIC RECOMBINANT HUMAN

> ADD > INJECTABLE; INJECTION
> ADD > OVIDREL
> ADD > + SERONO 0.25MG/VIAL N21149 001
> ADD > SEP 20, 2000

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN
AT IPHARM 0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML N62818 001
OCT 11, 1988
@ 0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML N62818 001
OCT 11, 1988

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL
RAXAR
GLAXO WELLCOME EQ 200MG BASE N20695 001
NOV 06, 1997
EQ 400MG BASE N20695 002
MAY 14, 1998
* EQ 600MG BASE N20695 003
MAY 14, 1998
OTSUKA EQ 200MG BASE N20695 001
NOV 06, 1997
EQ 400MG BASE N20695 002
MAY 14, 1998
+ EQ 600MG BASE N20695 003
MAY 14, 1998

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL
GRIS-PEG
AB ALLERGAN HERBERT 125MG N50475 001
AB 250MG N50475 002
AB PEDINOL 125MG N50475 001
AB 250MG N50475 002

> DLT >
> DLT >
> DLT >
> DLT >
> ADD >
> ADD >
> ADD >
> ADD >

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE
AO APOTEX EQ 50MG BASE/ML N75440 001
FEB 28, 2000
AO EQ 100MG BASE/ML N75440 002
FEB 28, 2000
AO KING PHARMS EQ 50MG BASE/ML N75176 001
FEB 09, 2000
AO EQ 100MG BASE/ML N75176 002
FEB 09, 2000

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN LOCK FLUSH
AP SMITH AND NEPHEW 10 UNITS/ML N87904 001
APR 20, 1983
AP 100 UNITS/ML N87906 001
APR 20, 1983
@ 10 UNITS/ML N87904 001
APR 20, 1983
@ 100 UNITS/ML N87906 001
APR 20, 1983
@ STERIS 100 UNITS/ML N17064 001
@ 100 UNITS/ML N17064 001
HEPARIN SODIUM
AP STERIS 5,000 UNITS/ML N17064 003
AP 10,000 UNITS/ML N17064 004
AP 20,000 UNITS/ML N17064 005
AP 40,000 UNITS/ML N17064 006
@ 5,000 UNITS/ML N17064 003
@ 10,000 UNITS/ML N17064 004
@ 20,000 UNITS/ML N17064 005
@ 40,000 UNITS/ML N17064 006

HEXACHLOROPHENE

> ADD > AEROSOL; TOPICAL
> ADD > SEPTISOL
> ADD > @ VESTAL LABS 0.23% N17424 001

> DLT > DISC; TOPICAL
> DLT > SEPTISOL
> DLT > * VESTAL LABS 0.23% N17424 001

HISTRELIN ACETATE

INJECTABLE; INJECTION

SUPPRELIN

*	ROBERTS LABS	EQ 0.2MG BASE/ML	N19836 001	> DLT >	
			DEC 24, 1991	> DLT >	
*		EQ 0.5MG BASE/ML	N19836 002	> ADD >	
			DEC 24, 1991	> ADD >	
*		EQ 1MG BASE/ML	N19836 003	> ADD >	
			DEC 24, 1991	> ADD >	
+	SHIRE LABS	EQ 0.2MG BASE/ML	N19836 001		
			DEC 24, 1991		
+		EQ 0.5MG BASE/ML	N19836 002		
			DEC 24, 1991		
+		EQ 1MG BASE/ML	N19836 003		
			DEC 24, 1991	> ADD >	
				> ADD >	
				> ADD >	
				> ADD >	
				> ADD >	
				> DLT >	
				> DLT >	

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HCL

AP	GENSIA SICOR PHARMS	20MG/ML	N40373 001	
			FEB 23, 2000	
AP	+ LUITPOLD	20MG/ML	N40136 001	
			JUN 30, 1997	
	*	20MG/ML	N40136 001	
			JUN 30, 1997	

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB	MYLAN	12.5MG	N75640 001
			JAN 28, 2000

MICROZIDE

AB	+ WATSON LABS	12.5MG	N20504 001
			DEC 27, 1996
	*	12.5MG	N20504 001
			DEC 27, 1996

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB	GLOBAL PHARM	100MG	N85098 001
	@ IMPAX LABS	100MG	N85098 001

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

*	MERCK	12.5MG;50MG	N20387 001
			APR 28, 1995
		12.5MG;50MG	N20387 001
			APR 28, 1995
+		25MG;100MG	N20387 002
			NOV 10, 1998

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

CODAMINE

AA	ALPHARMA	5MG/5ML;25MG/5ML	N75103 001
			SEP 29, 2000

HYCOMINE

AA	+ ENDO PHARMS	5MG/5ML;25MG/5ML	N19410 001
			AUG 17, 1990
	*	5MG/5ML;25MG/5ML	N19410 001
			AUG 17, 1990

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT	ZENITH GOLDLINE	1%	N85733 001
	@	1%	N85733 001

NOGENIC HC

AT	ZENITH GOLDLINE	1%	N87427 001
			APR 04, 1988
	@	1%	N87427 001
			APR 04, 1988

NUTRACORT

AT	GALDERMA LABS	0.5%	N80442 002
AT		1%	N80442 003
AT	HEALTHPOINT	1%	N80442 003
	@	0.5%	N80442 002

GEL; TOPICAL

NUTRACORT

	@ GALDERMA LABS	1%	N84698 001
	@ HEALTHPOINT	1%	N84698 001

LOTION; TOPICAL

HYDROCORTISONE

AT	ALTANA	2.5%	N40351 001
			JUL 25, 2000

HYDROCORTISONE

LOTION; TOPICAL
NUTRACORT

AT	GALDERMA LABS	0.5%	N80443 002	
AT		1%	N80443 003	
AT		2.5%	N87644 001	
			AUG 24, 1982	
AT	HEALTHPOINT	1%	N80443 003	
AT		2.5%	N87644 001	
			AUG 24, 1982	
	@	0.5%	N80443 002	

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62874 001
			MAY 11, 1988
AT	STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62874 001
			MAY 11, 1988

SUSPENSION/DROPS; OTIC
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62488 001
			NOV 06, 1985
AT	STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62488 001
			NOV 06, 1985

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL
EPIFOAM

BX	SCHWARZ PHARMA	1%;1%	N86457 001

PROCTOFOAM HC

BX	SCHWARZ PHARMA	1%;1%	N86195 001

DISC; TOPICAL
EPIFOAM

BX	SCHWARZ PHARMA	1%;1%	N86457 001

PROCTOFOAM HC

BX	SCHWARZ PHARMA	1%;1%	N86195 001

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL
LOCOID

	@ GALDERMA LABS	0.1%	N18795 001
			JAN 07, 1983
	@ YAMANOUCHI	0.1%	N18795 001
			JAN 07, 1983

LOCOID LIPOCREAM

	YAMANOUCHI	0.1%	N20769 001
			SEP 08, 1997
	+	0.1%	N20769 001
			SEP 08, 1997

OINTMENT; TOPICAL
LOCOID

	@ GALDERMA LABS	0.1%	N19106 001
			JUL 03, 1984
	@ YAMANOUCHI	0.1%	N19106 001
			JUL 03, 1984

SOLUTION; TOPICAL
LOCOID

	@ GALDERMA LABS	0.1%	N19819 001
			SEP 15, 1988
	@ YAMANOUCHI	0.1%	N19819 001
			SEP 15, 1988

HYDROCORTISONE VALERATE

CREAM; TOPICAL
HYDROCORTISONE VALERATE

AB	CLAY PARK	0.2%	N75666 001
			MAY 24, 2000

HYDROXYUREA

CAPSULE; ORAL
HYDROXYUREA

AB	BARR	250MG	N75143 002	
			SEP 21, 2000	
AB	DURAMED	250MG	N75020 002	> ADD >
			JUN 26, 2000	> ADD >
AB	+	250MG	N75020 002	> DLT >
			JUN 26, 2000	> DLT >
				> ADD >
				> ADD >

HYDROXYUREA

TABLET; ORAL
HYDROXYUREA
+ BARR 1GM N75734 001
AUG 29, 2000

INAMRINONE LACTATE

INJECTABLE; INJECTION
AMRINONE
AP BEDFORD EQ 5MG BASE/ML N75513 001
MAY 09, 2000

AMRINONE LACTATE
AP BAXTER PHARM PROD EQ 5MG BASE/ML N75542 001
MAY 10, 2000

INSULIN ASPART RECOMBINANT

INJECTABLE; INJECTION
NOVOLOG
+ NOVO NORDISK 100 UNITS/ML N20986 001
JUN 07, 2000

INSULIN GLARGINE

INJECTABLE; INJECTION
LANTUS
+ AVENTIS PHARMS 100 UNITS/ML N21081 001
APR 20, 2000

INSULIN LISPRO; INSULIN LISPRO PROTAMINE

INJECTABLE; INJECTION
HUMALOG MIX 50/50
+ LILLY 50 UNITS/ML;50 UNITS/ML N21018 001
DEC 22, 1999

HUMALOG MIX 75/25
+ LILLY 25 UNITS/ML;75 UNITS/ML N21017 001
DEC 22, 1999

INSULIN LISPRO PROTAMINE

INJECTABLE; INJECTION
HUMALOG MIX 50/50
+ LILLY 100 UNITS/ML N21018 001
DEC 22, 1999

HUMALOG MIX 75/25
+ LILLY 100 UNITS/ML N21017 001
DEC 22, 1999

INULIN

INJECTABLE; INJECTION
INULIN AND SODIUM CHLORIDE
+ CYPROS 100MG/ML N02282 001
+ QUESTCOR PHARM 100MG/ML N02282 001

IOPAMIDOL

INJECTABLE; INJECTION
IOPAMIDOL-200
AP COOK IMAGING 41% N74881 001
JUL 28, 2000

IOPAMIDOL-250
AP COOK IMAGING 51% N74881 002
JUL 28, 2000

IOPAMIDOL-300
AP COOK IMAGING 61% N74881 003
JUL 28, 2000

IOPAMIDOL-370
AP COOK IMAGING 76% N74881 004
JUL 28, 2000

IOTHALAMATE SODIUM, I-125

INJECTABLE; INJECTION
GLOFIL-125
CYPROS 250-300 uCi/ML N17279 001
QUESTCOR PHARM 250-300 uCi/ML N17279 001

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
IPRATROPIUM BROMIDE
AN STERIPAK 0.02% N75313 001
FEB 07, 2000

ISOCARBOXAZID

TABLET; ORAL
MARPLAN
+ OXFORD PHARM 10MG N11961 001

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
BRONKOSOL
AN + SANOFI SYNTHELABO 1% N12339 008
@ 1% N12339 008
ISOETHARINE HCL
AN ROXANE 1% N86899 001
AN + 1% N86899 001

ISOETHARINE MESYLATE

AEROSOL, METERED; INHALATION
BRONKOMETER
+ SANOFI SYNTHELABO 0.34MG/INH N12339 007
@ 0.34MG/INH N12339 007

ISOFLURANE

LIQUID; INHALATION
ISOFLURANE
AN RHODIA 99.9% N74502 001
JUN 27, 1995
AN RHONE POULENC 99.9% N74502 001
JUN 27, 1995

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION
ISUPREL
+ SANOFI SYNTHELABO 0.103MG/INH N11178 001
@ 0.103MG/INH N11178 001

SOLUTION; INHALATION
ISUPREL
+ SANOFI SYNTHELABO 0.5% N06327 002 > ADD >
+ 1% N06327 003 > ADD >
@ 0.5% N06327 002
@ 1% N06327 003

ISOSORBIDE DINITRATE

TABLET, EXTENDED RELEASE; ORAL
ISORDIL
AB + WYETH AYERST 40MG N12882 001
JUL 29, 1988
@ 40MG N12882 001
JUL 29, 1988
ISOSORBIDE DINITRATE
AB INWOOD LABS 40MG N40009 001
DEC 30, 1998
+ 40MG N40009 001
DEC 30, 1998

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL
IMDUR
AB + SCHERING 120MG N20225 003
MAR 30, 1995
+ 120MG N20225 003
MAR 30, 1995
ISOSORBIDE MONONITRATE
AB DEXCEL LTD 60MG N75522 001
APR 17, 2000
AB KREMERS URBAN 30MG N75155 002
JAN 13, 2000
AB 120MG N75155 003
AUG 04, 2000
AB KV PHARM 30MG N75395 001
MAR 16, 2000
AB 60MG N75395 002
MAR 16, 2000
AB 120MG N75395 003
MAR 16, 2000
AB ZENITH GOLDLINE 60MG N75448 001
JUN 19, 2000

IVERMECTIN

TABLET; ORAL
STROMECTOL
MERCK 3MG N50742 002
OCT 08, 1998

KANAMYCIN SULFATE

INJECTABLE; INJECTION
KANAMYCIN SULFATE

> DLT >	AP	PHARMAFAIR	EQ 75MG BASE/2ML	N62668 001 MAY 07, 1987
> DLT >				
> DLT >	AP		EQ 500MG BASE/2ML	N62672 001 MAY 07, 1987
> DLT >				
> DLT >	AP		EQ 1GM BASE/3ML	N62669 001 MAY 07, 1987
> DLT >				
> ADD >		@	EQ 75MG BASE/2ML	N62668 001 MAY 07, 1987
> ADD >				
> ADD >		@	EQ 500MG BASE/2ML	N62672 001 MAY 07, 1987
> ADD >				
> ADD >		@	EQ 1GM BASE/3ML	N62669 001 MAY 07, 1987
> ADD >				

KETOCONAZOLE

CREAM; TOPICAL
KETOCONAZOLE

AB		TEVA	2%	N75581 001 APR 25, 2000

NIZORAL

AB	+	MCNEIL CONS	2%	N19084 001 DEC 31, 1985
	*		2%	N19084 001 DEC 31, 1985

SHAMPOO; TOPICAL
NIZORAL

	+	JANSSEN	2%	N19927 001 AUG 31, 1990
	+	MCNEIL CONS	2%	N19927 001 AUG 31, 1990

LACTULOSE

SOLUTION; ORAL
DUPHALAC

AA		SOLVAY	10GM/15ML	N72372 001 MAR 22, 1989
	@		10GM/15ML	N72372 001 MAR 22, 1989

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP	+	ABBOTT	EQ 10MG BASE/ML	N40147 001 JUN 25, 1997
	*		EQ 10MG BASE/ML	N40147 001 JUN 25, 1997
AP		BEDFORD	EQ 10MG BASE/ML	N40347 001 APR 25, 2000
AP			EQ 350MG BASE/VIAL	N40335 001 APR 20, 2000

WELLCOVORIN

AP		GLAXO WELLCOME	EQ 100MG BASE/VIAL	N89834 001 JAN 23, 1989
	@		EQ 100MG BASE/VIAL	N89834 001 JAN 23, 1989

TABLET; ORAL
LEUCOVORIN CALCIUM

> DLT >	AB	+	IMMUNEX	EQ 15MG BASE	N71104 001 MAR 04, 1987
> DLT >					
> ADD >	AB			EQ 15MG BASE	N71104 001 MAR 04, 1987
> ADD >					
> DLT >	AB		ROXANE	EQ 25MG BASE	N72736 001 FEB 22, 1993
> DLT >					
> ADD >	AB	+		EQ 25MG BASE	N72736 001 FEB 22, 1993
> ADD >					

LEUPROLIDE ACETATE

IMPLANT; IMPLANTATION
VIADUR

	+	ALZA	EQ 65MG BASE	N21088 001 MAR 03, 2000

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC
BETAXON

	+	ALCON	EQ 0.5% BASE	N21114 001 FEB 23, 2000

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
LEVOBUNOLOL HCL

AT	NOVEX	0.25%	N75473 001	AUG 03, 2000
AT		0.5%	N75475 001	AUG 03, 2000

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHIROCAINE

	PURDUE PHARMA	EQ 2.5MG BASE/ML	N20997 001	AUG 05, 1999
		EQ 5MG BASE/ML	N20997 002	AUG 05, 1999
*		EQ 7.5MG BASE/ML	N20997 003	AUG 05, 1999
	PURDUE PHARMA LP	EQ 2.5MG BASE/ML	N20997 001	AUG 05, 1999
		EQ 5MG BASE/ML	N20997 002	AUG 05, 1999
+		EQ 7.5MG BASE/ML	N20997 003	AUG 05, 1999

LEVOFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
QUIXIN

+	SANTEN	0.5%	N21199 001	AUG 18, 2000

TABLET; ORAL
LEVAQUIN

> DLT >	* JOHNSON RW	500MG	N20634 002	DEC 20, 1996
> DLT >				
> ADD >		500MG	N20634 002	DEC 20, 1996
> ADD >				
> ADD >	+	750MG	N20634 003	SEP 08, 2000
> ADD >				

LEVORPHANOL TARTRATE

TABLET; ORAL
LEVO-DROMORAN

AB	+ ICN	2MG	N08720 001	DEC 19, 1991
	*	2MG	N08720 001	DEC 19, 1991

LEVORPHANOL TARTRATE

AB	ROXANE	2MG	N74278 001	MAR 31, 2000

LEVOTHYROXINE SODIUM

TABLET; ORAL
UNITHROID

	STEVENS J	0.025MG	N21210 001	AUG 21, 2000
		0.05MG	N21210 002	AUG 21, 2000
		0.075MG	N21210 003	AUG 21, 2000
		0.088MG	N21210 004	AUG 21, 2000
		0.1MG	N21210 005	AUG 21, 2000
		0.112MG	N21210 006	AUG 21, 2000
		0.125MG	N21210 007	AUG 21, 2000
		0.15MG	N21210 008	AUG 21, 2000
		0.175MG	N21210 009	AUG 21, 2000
		0.2MG	N21210 010	AUG 21, 2000
+		0.3MG	N21210 011	AUG 21, 2000

LINEZOLID

GRANULE, FOR RECONSTITUTION; ORAL
ZYVOX

+	PHARMACIA AND UPJOHN	100MG/5ML	N21132 001	APR 18, 2000

LINEZOLID

INJECTABLE; INJECTION
ZYVOX
+ PHARMACIA AND UPJOHN 200MG/100ML N21131 001 APR 18, 2000

TABLET; ORAL
ZYVOX
PHARMACIA AND UPJOHN 400MG N21130 001 APR 18, 2000
+ 600MG N21130 002 APR 18, 2000

> ADD > LOPINAVIR; RITONAVIR

> ADD > CAPSULE; ORAL
> ADD > KALETRA
> ADD > + ABBOTT 133.3MG;33.3MG N21226 001 SEP 15, 2000
> ADD >

> ADD > SOLUTION; ORAL
> ADD > KALETRA
> ADD > + ABBOTT 80MG/ML;20MG/ML N21251 001 SEP 15, 2000
> ADD >

LORAZEPAM

INJECTABLE; INJECTION
LORAZEPAM
AP MOVA 2MG/ML N74793 001 MAR 16, 2000
AP 4MG/ML N74793 002 MAR 16, 2000

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE
AP ABBOTT 500MG/ML N75151 001 APR 25, 2000
AP + AM PHARM PARTNERS 500MG/ML N19316 001 SEP 08, 1986
* 500MG/ML N19316 001 SEP 08, 1986

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL
AMEN
BP AMARIN PHARMS 10MG N83242 001
BP CARNRICK 10MG N83242 001

MEGESTROL ACETATE

TABLET; ORAL
MEGESTROL ACETATE
AB PHARMACHEMIE 40MG N74745 001 FEB 27, 1998
AB TEVA 40MG N74745 001 FEB 27, 1998

MELOXICAM

TABLET; ORAL
MOBIC
+ BOEHRINGER INGELHEIM 7.5MG N20938 001 APR 13, 2000

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION
MENOTROPINS
@ FERRING 75 IU/VIAL;75 IU/VIAL N73598 001 JAN 30, 1997
@ 150 IU/VIAL;150 IU/VIAL N73599 001 JAN 30, 1997
REPRONEX
AB FERRING 75 IU/VIAL;75 IU/VIAL N73598 001 JAN 30, 1997
AB 150 IU/VIAL;150 IU/VIAL N73599 001 JAN 30, 1997

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL
MEPERIDINE HCL
AA MALLINCKRODT 50MG N40352 001 JUN 13, 2000
AA 100MG N40352 002 JUN 13, 2000

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION
WYAMINE SULFATE

	+	WYETH AYERST	EQ 30MG BASE/ML	N08248 001
	@		EQ 30MG BASE/ML	N08248 001

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

> DLT >	AA	LANNETT	200MG	N14882 002
> DLT >	AA		400MG	N14882 001
> ADD >		@	200MG	N14882 002
> ADD >		@	400MG	N14882 001

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL
PENTASA

	+	ROBERTS LABS	250MG	N20049 001 MAY 10, 1993
	+	SHIRE LABS	250MG	N20049 001 MAY 10, 1993

SUPPOSITORY; RECTAL
ROWASA

	+	SOLVAY	500MG	N19919 001 DEC 18, 1990
	@		500MG	N19919 001 DEC 18, 1990

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20
NORINYL

	@	SEARLE	0.1MG;2MG	N13625 004
	@	WATSON LABS	0.1MG;2MG	N13625 004

TABLET; ORAL-21
NORINYL 1+50 21-DAY

AB		SEARLE	0.05MG;1MG	N13625 002
AB		WATSON LABS	0.05MG;1MG	N13625 002

METAPROTERENOL SULFATE

SOLUTION; INHALATION
ALUPENT

AN	+	BOEHRINGER INGELHEIM	5%	N17659 001
	+		5%	N17659 001

PROMETA

AN		MURO	5%	N73340 001 MAR 30, 1992
	@		5%	N73340 001 MAR 30, 1992

SYRUP; ORAL
METAPROTERENOL SULFATE

AA		NOVEX	10MG/5ML	N75235 001 JAN 27, 2000

METHANTHELINE BROMIDE

TABLET; ORAL
BANTHINE

	+	ROBERTS LABS	50MG	N07390 001
	+	SHIRE LABS	50MG	N07390 001

METHIMAZOLE

TABLET; ORAL
METHIMAZOLE

AB		APPLIED ANAL	5MG	N40320 001 MAR 31, 2000
AB			10MG	N40320 002 MAR 31, 2000
AB		GENPHARM	5MG	N40350 001 MAR 29, 2000
AB			10MG	N40350 002 MAR 29, 2000
AB		JONES PHARMA	5MG	N40320 001 MAR 31, 2000
AB			10MG	N40320 002 MAR 31, 2000

TAPAZOLE

AB		LILLY	5MG	N07517 002
AB	+		10MG	N07517 004
	+		5MG	N07517 002
	+		10MG	N07517 004

METHOXYFLURANE

LIQUID; INHALATION
PENTHRANE
+ ABBOTT 99.9% N13056 001
@ 99.9% N13056 001

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
CONCERTA
+ ALZA 18MG N21121 001 AUG 01, 2000
+ 36MG N21121 002 AUG 01, 2000

METADATE ER
AB + MEDEVA 10MG N40306 001 OCT 20, 1999
* 10MG N40306 001 OCT 20, 1999

METHYLIN ER
AB MALLINCKRODT 10MG N75629 001 MAY 09, 2000
AB 20MG N75629 002 MAY 09, 2000

METHYLTESTOSTERONE

TABLET; ORAL
ORETON METHYL
BP SCHERING 10MG N03158 001
BP 25MG N03158 002
@ 10MG N03158 001
@ 25MG N03158 002

MICONAZOLE NITRATE

INSERT, CREAM; VAGINAL, TOPICAL
MONISTAT DUAL- PAK
+ ADVANCED CARE PRODS 1.2GM,2% N20968 001 JUN 30, 1999
+ PERSONAL PRODS 1.2GM,2% N20968 001 JUN 30, 1999

TAMPON; VAGINAL
MONISTAT 5
@ ADVANCED CARE PRODS 100MG N18592 001 OCT 27, 1989

MICONAZOLE NITRATE

TAMPON; VAGINAL
MONISTAT 5
@ PERSONAL PRODS 100MG N18592 001 OCT 27, 1989

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HCL
AP ABBOTT EQ 1MG BASE/ML N75293 001 JUN 20, 2000
AP EQ 1MG BASE/ML N75409 002 JUN 20, 2000
AP EQ 5MG BASE/ML N75293 002 JUN 20, 2000
AP EQ 5MG BASE/ML N75409 001 JUN 20, 2000
AP AESGEN EQ 1MG BASE/ML N75154 002 JUN 20, 2000
AP EQ 5MG BASE/ML N75154 001 JUN 20, 2000
AP ASTRAZENECA PHARMS EQ 5MG BASE/ML N75263 001 JUN 26, 2000
AP BAXTER PHARM PROD EQ 1MG BASE/ML N75324 001 JUN 20, 2000
AP EQ 5MG BASE/ML N75324 002 JUN 20, 2000
AP BEDFORD EQ 1MG BASE/ML N75247 002 JUN 23, 2000
AP EQ 5MG BASE/ML N75247 001 JUN 23, 2000
AP EQ 5MG BASE/ML N75249 001 JUN 23, 2000
AP BEN VENUE EQ 1MG BASE/ML N75421 002 JUN 20, 2000
AP EQ 5MG BASE/ML N75421 001 JUN 20, 2000
AP EQ 5MG BASE/ML N75455 001 JUN 20, 2000
AP ESI LEDERLE EQ 1MG BASE/ML N75243 001 JUN 20, 2000
AP EQ 5MG BASE/ML N75243 002 JUN 20, 2000
AP FAULDING EQ 1MG BASE/ML N75396 001 JUN 20, 2000

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

		MIDAZOLAM HCL			
AP		FAULDING	EQ 5MG BASE/ML	N75396 002 JUN 20, 2000	
AP			EQ 5MG BASE/ML	N75484 001 JUN 20, 2000	
AP		TAYLOR	EQ 5MG BASE/ML	N75481 001 JUN 30, 2000	
AP		TAYLOR PHARMA	EQ 1MG BASE/ML	N75494 001 JUN 30, 2000	
AP			EQ 5MG BASE/ML	N75494 002 JUN 30, 2000	
		VERSED			
AP	+	HLR	EQ 1MG BASE/ML	N18654 002 MAY 26, 1987	
AP	+		EQ 5MG BASE/ML	N18654 001 DEC 20, 1985	
AP	+	ROCHE	EQ 1MG BASE/ML	N18654 002 MAY 26, 1987	
AP	+		EQ 5MG BASE/ML	N18654 001 DEC 20, 1985	

> ADD > MIFEPRISTONE

> ADD > TABLET; ORAL

> ADD >		**MIFEPREX**			
> ADD >	+	POPULATION COUNCIL	200MG	N20687 001 SEP 28, 2000	

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

		MINOCIN			
AB	+	LEDERLE	EQ 100MG BASE	N50649 002 MAY 31, 1990	
AB			EQ 100MG BASE	N50649 002 MAY 31, 1990	
		MINOCYCLINE HCL			
AB	+	DANBURY PHARMA	EQ 75MG BASE	N63065 002 JUN 10, 1999	
AB			EQ 75MG BASE	N63065 002 JUN 10, 1999	
AB			EQ 100MG BASE	N63065 001 DEC 30, 1991	

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

		MINOCYCLINE HCL			
AB	+	DANBURY PHARMA	EQ 100MG BASE	N63065 001 DEC 30, 1991	

MONTELUKAST SODIUM

TABLET, CHEWABLE; ORAL

	SINGULAIR			
	MERCK	EQ 4MG BASE	N20830 002 MAR 03, 2000	

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

		MORPHINE SULFATE			
> ADD >	AB	ENDO PHARMS	100MG	N75295 004 SEP 15, 2000	
> ADD >	AB		200MG	N75295 005 SEP 15, 2000	
> ADD >	AB	ESI LEDERLE	15MG	N75407 001 JAN 28, 2000	

NABUMETONE

TABLET; ORAL

		NABUMETONE			
AB		COPLEY PHARM	750MG	N75179 001 JUN 06, 2000	
AB		TEVA	500MG	N75189 001 MAY 26, 2000	
		RELAFEN			
AB		SMITHKLINE BEECHAM	500MG	N19583 001 DEC 24, 1991	
AB	+		750MG	N19583 002 DEC 24, 1991	
			500MG	N19583 001 DEC 24, 1991	
	+		750MG	N19583 002 DEC 24, 1991	

NADOLOL

TABLET; ORAL

	CORGARD				
AB	APOTHECON	40MG	N18063 001		N75061 001 FEB 18, 1998
AB +		40MG	N18063 001		N75061 002 FEB 18, 1998

NAFCILLIN SODIUM

TABLET; ORAL

	UNIPEN				
* @	WYETH AYERST	EQ 500MG BASE	N50462 001		N75061 001 FEB 18, 1998
		EQ 500MG BASE	N50462 001		N75061 002 FEB 18, 1998

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION

	REVEX				
+	BAXTER PHARM PROD	EQ 0.1MG BASE/ML	N20459 001 APR 17, 1995		N83115 001
+		EQ 1MG BASE/ML	N20459 002 APR 17, 1995		N83115 001
*	OHMEDA	EQ 0.1MG BASE/ML	N20459 001 APR 17, 1995		N40378 001 MAY 03, 2000
*		EQ 1MG BASE/ML	N20459 002 APR 17, 1995		N40378 001 MAY 03, 2000

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

	PENTAZOCINE AND NALOXONE HYDROCHLORIDES	EQ 0.5MG BASE; EQ 50MG BASE			
AB	RANBAXY		N75523 001 MAR 17, 2000	> ADD > > ADD >	N20198 001 APR 21, 1993

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

	NALTREXONE HCL				
AB	EON	50MG	N75434 001 MAR 08, 2000	> ADD > > ADD > > DLT > > DLT >	N20198 001 APR 21, 1993

NAPROXEN

TABLET, DELAYED RELEASE; ORAL

	NAPROXEN				
AB	GENEVA PHARMS TECH	375MG	N75061 001 FEB 18, 1998		N75289 001 SEP 27, 2000
AB		500MG	N75061 002 FEB 18, 1998		N75128 001 MAR 10, 2000
AB	INVAMED	375MG	N75061 001 FEB 18, 1998		N19684 002 SEP 06, 1989
AB		500MG	N75061 002 FEB 18, 1998		N19684 002 SEP 06, 1989

NIACIN

TABLET; ORAL

	NIACIN				
AA	GLOBAL PHARM	500MG	N83115 001		N40378 001 MAY 03, 2000
@	IMPAX LABS	500MG	N83115 001		N40378 001 MAY 03, 2000
	NIACOR				
AA	UPSHER SMITH	500MG	N40378 001 MAY 03, 2000		

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

	ADALAT CC				
AB +	BAYER	30MG	N20198 001 APR 21, 1993		
BC *		30MG	N20198 001 APR 21, 1993		
	NIFEDIPINE				
AB	BIOVAIL	60MG	N75289 001 SEP 27, 2000		
AB	ELAN PHARM	30MG	N75128 001 MAR 10, 2000		
	PROCARDIA XL				
AB +	PFIZER	60MG	N19684 002 SEP 06, 1989		
BC *		60MG	N19684 002 SEP 06, 1989		

NITROFURAZONE

CREAM; TOPICAL

	FURACIN				
*	ROBERTS LABS	0.2%	N83789 001		

NITROFURAZONE

CREAM; TOPICAL
FURACIN

	+	SHIRE LABS	0.2%	N83789 001

OINTMENT; TOPICAL
FURACIN

AT	*	ROBERTS LABS	0.2%	N05795 001
AT	+	SHIRE LABS	0.2%	N05795 001

NITROGLYCERIN

INJECTABLE; INJECTION
NITRO IV

> DLT >				
> DLT >	AP	* POHL BOSKAMP	5MG/ML	N18672 002 AUG 30, 1983
> DLT >				
> ADD >		@	5MG/ML	N18672 002 AUG 30, 1983
> ADD >				

TABLET; SUBLINGUAL
NITROSTAT

		PARKE DAVIS	0.3MG	N21134 001 MAY 01, 2000
			0.4MG	N21134 002 MAY 01, 2000
	+		0.6MG	N21134 003 MAY 01, 2000

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
NORTRIPTYLINE HCL

AB	TARO	EQ 10MG BASE	N75520 004 MAY 08, 2000
AB		EQ 25MG BASE	N75520 003 MAY 08, 2000
AB		EQ 50MG BASE	N75520 001 MAY 08, 2000
AB		EQ 75MG BASE	N75520 002 MAY 08, 2000

SOLUTION; ORAL
NORTRIPTYLINE HCL

AA	PHARM ASSOC	EQ 10MG BASE/5ML	N75606 001 AUG 28, 2000

NYSTATIN

TABLET; VAGINAL
NYSTATIN

AT	ODYSSEY PHARMS	100,000 UNITS	N62615 001 OCT 17, 1985
AT	SIDMAK LABS NJ	100,000 UNITS	N62615 001 OCT 17, 1985

OCTREOTIDE ACETATE

INJECTABLE; INJECTION
SANDOSTATIN

	NOVARTIS	EQ 0.2MG BASE/ML	N19667 004 JUN 12, 1991
		EQ 1MG BASE/ML	N19667 005 JUN 12, 1991
+		EQ 0.2MG BASE/ML	N19667 004 JUN 12, 1991
+		EQ 1MG BASE/ML	N19667 005 JUN 12, 1991

SANDOSTATIN LAR

	NOVARTIS	EQ 10MG BASE/VIAL	N21008 001 NOV 25, 1998
		EQ 20MG BASE/VIAL	N21008 002 NOV 25, 1998
+		EQ 10MG BASE/VIAL	N21008 001 NOV 25, 1998
+		EQ 20MG BASE/VIAL	N21008 002 NOV 25, 1998

OLANZAPINE

TABLET; ORAL
ZYPREXA

	LILLY	2.5MG	N20592 001 SEP 30, 1996
*		10MG	N20592 004 SEP 30, 1996
@		15MG	N20592 005 SEP 09, 1997
+		2.5MG	N20592 001 SEP 30, 1996
		10MG	N20592 004 SEP 30, 1996
+		15MG	N20592 005 SEP 09, 1997

OLANZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

	ZYPREXA ZYDIS LILLY	5MG	N21086 001 APR 06, 2000	
		10MG	N21086 002 APR 06, 2000	
		15MG	N21086 003 APR 06, 2000	
+		20MG	N21086 004 APR 06, 2000	

ORLISTAT

CAPSULE; ORAL

	XENICAL			
+	HLR	120MG	N20766 001 APR 23, 1999	
*	ROCHE	120MG	N20766 001 APR 23, 1999	

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

	ORPHENADRINE CITRATE			
AB	EON	100MG	N40327 001 FEB 15, 2000	
AB	GENEVA PHARMS TECH	100MG	N40284 001 JUN 19, 1998	
AB	IMPAX PHARM	100MG	N40368 001 JUN 23, 2000	
AB	INVAMED	100MG	N40284 001 JUN 19, 1998	

OXCARBAZEPINE

TABLET; ORAL

	TRILEPTAL NOVARTIS	150MG	N21014 001 JAN 14, 2000	> ADD >
		300MG	N21014 002 JAN 14, 2000	> ADD >
+		600MG	N21014 003 JAN 14, 2000	> ADD > > DLT > > DLT >

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	DITROPAN XL			
AB	* ALZA	5MG	N20897 001 DEC 16, 1998	
	+	5MG	N20897 001 DEC 16, 1998	

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

	ROXICODONE ROXANE	15MG	N21011 001 AUG 31, 2000	
	+	30MG	N21011 002 AUG 31, 2000	

TABLET, EXTENDED RELEASE; ORAL

	OXYCONTIN			
BX	* PURDUE PHARMA	10MG	N20553 001 DEC 12, 1995	
	+ PURDUE PHARMA LP	10MG	N20553 001 DEC 12, 1995	
	+	160MG	N20553 005 MAR 15, 2000	
	ROXICODONE			
BX	ROXANE	10MG	N20932 001 OCT 26, 1998	
	*	30MG	N20932 002 OCT 26, 1998	
	@	10MG	N20932 001 OCT 26, 1998	
	@	30MG	N20932 002 OCT 26, 1998	

PACLITAXEL

INJECTABLE; INJECTION

	PACLITAXEL			
AP	BAKER NORTON	6MG/ML	N75184 001 SEP 15, 2000	
	TAXOL			
AP	+ BRISTOL MYERS SQUIBB	6MG/ML	N20262 001 DEC 29, 1992	
	*	6MG/ML	N20262 001 DEC 29, 1992	

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL
PROTONIX

	+	WYETH AYERST	EQ 40MG BASE	N20987 001 FEB 02, 2000

PEMOLINE

TABLET; ORAL
PEMOLINE

AB	AMIDE PHARM	18.75MG	N75595 001 FEB 28, 2000
AB		37.5MG	N75595 002 FEB 28, 2000
AB		75MG	N75595 003 FEB 28, 2000
AB	COPLEY PHARM	18.75MG	N75030 003 FEB 22, 2000
AB	GENEVA PHARMS TECH	18.75MG	N75286 001 DEC 27, 1999
AB		37.5MG	N75286 002 JUN 30, 1999
AB		75MG	N75286 003 JUN 30, 1999
AB	INVAMED	18.75MG	N75286 001 DEC 27, 1999
AB		37.5MG	N75286 002 JUN 30, 1999
AB		75MG	N75286 003 JUN 30, 1999
AB	VINTAGE PHARMS	18.75MG	N75328 001 APR 19, 2000
AB		37.5MG	N75328 002 APR 19, 2000
AB		75MG	N75328 003 APR 19, 2000
> ADD > AB	WATSON LABS	37.5MG	N75287 002 SEP 18, 2000
> ADD > AB		75MG	N75287 003 SEP 18, 2000

TABLET, CHEWABLE; ORAL
CYLERT

AB	+	ABBOTT	37.5MG	N17703 001
	*		37.5MG	N17703 001

PEMOLINE

AB	AMIDE PHARM	37.5MG	N75678 001 JUL 26, 2000

PEMOLINE

TABLET, CHEWABLE; ORAL
PEMOLINE

AB	COPLEY PHARM	37.5MG	N75555 001 FEB 18, 2000

PENICILLIN G PROCAINE

INJECTABLE; INJECTION
WYCILLIN

AP	KING PHARMS	300,000 UNITS/ML	N60101 002
AP		600,000 UNITS/ML	N60101 001
AP	WYETH AYERST	300,000 UNITS/ML	N60101 002
AP		600,000 UNITS/ML	N60101 001

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION
PENTACARINAT

AP	ARMOUR PHARM	300MG/VIAL	N73447 001 APR 28, 1994
	@	300MG/VIAL	N73447 001 APR 28, 1994

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

AB	IMPAX LABS	400MG	N75093 001 AUG 10, 1999
AB	IMPAX PHARM	400MG	N75093 001 AUG 10, 1999

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

PASTE; TOPICAL
SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS

+	US ARMY	50%;50%	N21084 001 FEB 17, 2000

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON

	@	SOLVAY	2MG	N20184 001 DEC 30, 1993
	@		4MG	N20184 002 DEC 30, 1993
	@		8MG	N20184 003 DEC 30, 1993
		SOLVAY PHARMA	2MG	N20184 001 DEC 30, 1993
			4MG	N20184 002 DEC 30, 1993
	+		8MG	N20184 003 DEC 30, 1993

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
BONTRIL PDM

	AA	AMARIN PHARMS	35MG	N85272 001
	AA	CARNRICK	35MG	N85272 001

CAM-METRAZINE

> DLT >	AA	CAMALL	35MG	N83922 001
> ADD >	AA +		35MG	N83922 001

> DLT > PLEGINE

> DLT >	AA +	WYETH AYERST	35MG	N12248 001
> ADD >	@		35MG	N12248 001

PHYTONADIONE

INJECTABLE; INJECTION
> DLT > KONAKION

> DLT >	BP	ROCHE	1MG/0.5ML	N11745 001
> DLT >	BP		10MG/ML	N11745 003
> ADD >	@		1MG/0.5ML	N11745 001
> ADD >	@		10MG/ML	N11745 003

PIROXICAM

CAPSULE; ORAL
PIROXICAM

	AB	ROXANE	10MG	N73651 001 FEB 26, 1993

PIROXICAM

CAPSULE; ORAL
PIROXICAM

	AB	ROXANE	20MG	N73651 002 FEB 26, 1993
	@		10MG	N73651 001 FEB 26, 1993
	@		20MG	N73651 002 FEB 26, 1993

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL
K-DUR 10

	AB +	KEY PHARMS	10MEQ	N19439 002 JUN 13, 1986
	BC +		10MEQ	N19439 002 JUN 13, 1986

KLOR-CON M10

	AB	UPSHER SMITH	10MEQ	N74726 002 AUG 09, 2000

PREDNISOLONE

SYRUP; ORAL
PREDNISOLONE

	AA	COPLEY PHARM	15MG/5ML	N40322 001 JAN 19, 2000

TABLET; ORAL
PREDNISOLONE

	BX	GLOBAL PHARM	5MG	N80780 001
	@	IMPAX LABS	5MG	N80780 001
	BX	PHOENIX LABS NY	5MG	N80322 001
	@		5MG	N80322 001

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC
PREDNISOLONE SODIUM PHOSPHATE

	AT	ALCON UNIVERSAL	EQ 0.11% PHOSPHATE	N81043 001 OCT 24, 1991
	AT		EQ 0.9% PHOSPHATE	N81044 001 OCT 24, 1991

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC
PREDNISOLONE SODIUM PHOSPHATE

AT	STERIS	EQ 0.11% PHOSPHATE		N81043 001 OCT 24, 1991
AT		EQ 0.9% PHOSPHATE		N81044 001 OCT 24, 1991

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	ALCON UNIVERSAL	EQ 0.23% PHOSPHATE;10%	N73630 001 MAY 27, 1993
AT	STERIS	EQ 0.23% PHOSPHATE;10%	N73630 001 MAY 27, 1993

PREDNISONE

SYRUP; ORAL
LIQUID PRED

	+	MURO	5MG/5ML	N87611 002 SEP 07, 1982
	@		5MG/5ML	N87611 002 SEP 07, 1982

TABLET; ORAL
PREDNICEN-M

AB	CENT PHARMS	5MG	N84655 001
	@ SCHWARZ PHARMA	5MG	N84655 001

PREDNISONE

BX	PHOENIX LABS NY	5MG	N80321 001
BX		20MG	N83807 001
	@	5MG	N80321 001
	@	20MG	N83807 001

PROCHLORPERAZINE

SUPPOSITORY; RECTAL
COMPRO

AB	PADDOCK	25MG	N40246 001 JUN 28, 2000

PROGESTERONE

CAPSULE; ORAL
PROMETRIUM

	SCHERING PLOUGH	100MG	N19781 001 MAY 14, 1998
		200MG	N19781 002 OCT 15, 1999
	*	300MG	N19781 003 OCT 15, 1999
	UNIMED PHARMS	100MG	N19781 001 MAY 14, 1998
	+	200MG	N19781 002 OCT 15, 1999
	@	300MG	N19781 003 OCT 15, 1999

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL

AP	ABBOTT	25MG/ML	N40372 001 JUN 08, 2000
AP		50MG/ML	N40372 002 JUN 08, 2000

PROPANTHELINE BROMIDE

TABLET; ORAL
PRO-BANTHINE

BP	+	ROBERTS LABS	7.5MG	N08732 003
BP	*		15MG	N08732 002
BP	+	SHIRE LABS	7.5MG	N08732 003
BP	+		15MG	N08732 002

PROPARACAINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC
PROPARACAINE HCL

AT	TAYLOR PHARMA	0.5%	N40277 001 MAR 16, 2000

PROPOFOL

INJECTABLE; INJECTION
PROPOFOL
> ADD > AB GENSIA SICOR PHARMS 10MG/ML N75392 001
> ADD > SEP 19, 2000

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
INDERAL
AP + WYETH AYERST 1MG/ML N16419 001
+ 1MG/ML N16419 001
PROPRANOLOL HCL
AP BEDFORD 1MG/ML N75792 001
AUG 29, 2000

PROTOKYLOL HYDROCHLORIDE

TABLET; ORAL
VENTAIRE
@ AVENTIS PHARMS 2MG N83459 001
+ HOECHST MARION RSSL 2MG N83459 001

QUINIDINE POLYGALACTURONATE

> DLT > TABLET; ORAL
> DLT > CARDIOQUIN
> DLT > + PURDUE FREDERICK 275MG N11642 002
> ADD > @ 275MG N11642 002

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE
AB PHARMAVITE 200MG N84627 001
@ 200MG N84627 001

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE
AB RANBAXY EQ 150MG BASE N75439 001
APR 19, 2000

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE
AB RANBAXY EQ 300MG BASE N75439 002
APR 19, 2000

RESERPINE

TABLET; ORAL
RESERPINE
BP GLOBAL PHARM 0.1MG N09627 001
BP 0.25MG N09627 002
@ IMPAX LABS 0.1MG N09627 001
@ 0.25MG N09627 002

RISEDRONATE SODIUM

TABLET; ORAL
ACTONEL
> ADD > PROCTER AND GAMBLE 5MG N20835 002
> ADD > APR 14, 2000

RIVASTIGMINE TARTRATE

CAPSULE; ORAL
EXELON
NOVARTIS EQ 1.5MG BASE N20823 003
APR 21, 2000
EQ 3MG BASE N20823 004
APR 21, 2000
EQ 4.5MG BASE N20823 005
APR 21, 2000
+ EQ 6MG BASE N20823 006
APR 21, 2000

SOLUTION; ORAL
EXELON
+ NOVARTIS EQ 2MG BASE/ML N21025 001
APR 21, 2000

ROFECOXIB

TABLET; ORAL
VIOXX

>DLT>	+	MERCK	25MG	N21042 002
>DLT>				MAY 20, 1999
>ADD>			25MG	N21042 002
>ADD>				MAY 20, 1999
>ADD>	+		50MG	N21042 003
>ADD>				FEB 25, 2000

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE

AT		ZENITH GOLDLINE	2.5%	N85777 001
	@		2.5%	N85777 001

SEVELAMER HYDROCHLORIDE

TABLET; ORAL
RENAGEL

		GELTEX	400MG	N21179 001
				JUL 12, 2000
	+		800MG	N21179 002
				JUL 12, 2000

SIROLIMUS

TABLET; ORAL
RAPAMUNE

	+	WYETH AYERST	1MG	N21110 001
				AUG 25, 2000

SODIUM FLUORIDE, F-18

INJECTABLE; INTRAVENOUS
FLUORINE F-18

	@	NYCOMED AMERSHAM	2mCi/ML	N17042 001

>ADD> SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL
VISICOL

>ADD>	+	INKINE	0.398GM;1.102GM	N21097 001
>ADD>				SEP 21, 2000

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION
NORDITROPIN

		NOVO NORDISK	5MG/1.5ML	N21148 001
				JUN 20, 2000
			10MG/1.5ML	N21148 002
				JUN 20, 2000
	+		15MG/1.5ML	N21148 003
				JUN 20, 2000

SOTALOL HYDROCHLORIDE

TABLET; ORAL
BETAPACE

AB		BERLEX LABS	80MG	N19865 001
				OCT 30, 1992
AB			120MG	N19865 005
				APR 20, 1994
AB	+		160MG	N19865 002
				OCT 30, 1992
AB			240MG	N19865 003
				OCT 30, 1992
			80MG	N19865 001
				OCT 30, 1992
			120MG	N19865 005
				APR 20, 1994
	+		160MG	N19865 002
				OCT 30, 1992
			240MG	N19865 003
				OCT 30, 1992

BETAPACE AF

		BERLEX LABS	80MG	N21151 001
				FEB 22, 2000
			120MG	N21151 002
				FEB 22, 2000
	+		160MG	N21151 003
				FEB 22, 2000

SOTALOL HYDROCHLORIDE

TABLET; ORAL
SOTALOL HCL

AB	EON	80MG	N75366 001	MAY 01, 2000
AB		120MG	N75366 002	MAY 01, 2000
AB		160MG	N75366 003	MAY 01, 2000
AB		240MG	N75366 004	MAY 01, 2000
AB	GENPHARM	80MG	N75237 001	MAY 01, 2000
AB		120MG	N75237 002	MAY 01, 2000
AB		160MG	N75237 003	MAY 01, 2000
AB		240MG	N75237 004	MAY 01, 2000
AB	TEVA	80MG	N75429 001	MAY 01, 2000
AB		120MG	N75429 002	MAY 01, 2000
AB		160MG	N75429 003	MAY 01, 2000
AB		240MG	N75429 004	MAY 01, 2000
AB	WATSON LABS	80MG	N75238 001	JUL 13, 2000
AB		120MG	N75238 002	JUL 13, 2000
AB		160MG	N75238 003	JUL 13, 2000
AB		240MG	N75238 004	JUL 13, 2000

STRONTIUM CHLORIDE, SR-89

INJECTABLE; INJECTION
METASTRON

	NYCOMED AMERSHAM	1mCi/ML	N20134 001	JUN 18, 1993
+		1mCi/ML	N20134 001	JUN 18, 1993

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
OCUSULF-10

AT	MIZA PHARMS USA	10%	N80660 001	
AT	OPTOPICS	10%	N80660 001	

OCUSULF-30

@	MIZA PHARMS USA	30%	N80660 002	
@	OPTOPICS	30%	N80660 002	

SULFACETAMIDE SODIUM

AT	ALCON UNIVERSAL	10%	N89560 001	OCT 18, 1988
AT	STERIS	10%	N89560 001	OCT 18, 1988

TACRINE HYDROCHLORIDE

CAPSULE; ORAL
COGNEX

	FIRST HORIZON	EQ 10MG BASE	N20070 001	SEP 09, 1993
		EQ 20MG BASE	N20070 002	SEP 09, 1993
		EQ 30MG BASE	N20070 003	SEP 09, 1993
+		EQ 40MG BASE	N20070 004	SEP 09, 1993
	PARKE DAVIS PHARMS	EQ 10MG BASE	N20070 001	SEP 09, 1993
		EQ 20MG BASE	N20070 002	SEP 09, 1993
		EQ 30MG BASE	N20070 003	SEP 09, 1993
+		EQ 40MG BASE	N20070 004	SEP 09, 1993

TAMOXIFEN CITRATE

TABLET; ORAL
TAMOXIFEN CITRATE

@	MYLAN	EQ 10MG BASE	N74732 001	JUN 26, 2000
@	PHARMACHEMIE	EQ 10MG BASE	N74539 001	MAY 31, 2000

TAZAROTENE

> ADD > CREAM; TOPICAL
> ADD > TAZORAC
> ADD > ALLERGAN 0.05% N21184 001 SEP 29, 2000
> ADD >
> ADD > + 0.1% N21184 002 SEP 29, 2000
> ADD >

TELMISARTAN

TABLET; ORAL
MICARDIS
+ BOEHRINGER INGELHEIM 20MG N20850 003 APR 04, 2000

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
TERAZOSIN HCL

AB	INVAMED	**EQ 1MG BASE**	**N75667 001**	JUL 28, 2000
AB		**EQ 2MG BASE**	**N75667 002**	JUL 28, 2000
AB		EQ 5MG BASE	N75667 003	JUL 28, 2000
AB		**EQ 10MG BASE**	**N75667 004**	JUL 28, 2000
AB	MYLAN	**EQ 1MG BASE**	**N75140 002**	FEB 11, 2000
AB		**EQ 2MG BASE**	N75140 003	FEB 11, 2000
AB		**EQ 5MG BASE**	**N75140 001**	FEB 11, 2000
AB		**EQ 10MG BASE**	**N75140 004**	FEB 11, 2000

TABLET; ORAL
TERAZOSIN HCL

AB	INVAMED	**EQ 1MG BASE**	**N74657 001**	APR 28, 2000
AB		**EQ 2MG BASE**	**N74657 002**	APR 28, 2000
AB		**EQ 5MG BASE**	**N74657 003**	APR 28, 2000
AB		**EQ 10MG BASE**	**N74657 004**	APR 28, 2000

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL
TERAZOSIN HCL

AB	NOVOPHARM	**EQ 1MG BASE**	**N74446 001**	MAY 18, 2000
AB		**EQ 2MG BASE**	**N74446 002**	MAY 18, 2000
AB		**EQ 5MG BASE**	**N74446 003**	MAY 18, 2000
AB		**EQ 10MG BASE**	**N74446 004**	MAY 18, 2000
AB	ZENITH GOLDLINE	**EQ 1MG BASE**	**N74530 001**	APR 21, 2000
AB		**EQ 2MG BASE**	**N74530 002**	APR 21, 2000
AB		**EQ 5MG BASE**	**N74530 003**	APR 21, 2000
AB		**EQ 10MG BASE**	**N74530 004**	APR 21, 2000

TERBUTALINE SULFATE

> DLT > AEROSOL, METERED; INHALATION
> DLT > BRETHAIRE
> DLT > NOVARTIS 0.2MG/INH N18762 001 AUG 17, 1984
> ADD > @ 0.2MG/INH N18762 001 AUG 17, 1984
> ADD >

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
ANDRODERM

BX	**+ THERATECH**	**5MG/24HR**	**N20489 002**	**MAY 02, 1997**
	+	**2.5MG/24HR**	**N20489 001**	**SEP 29, 1995**
BX	+ WATSON LABS	5MG/24HR	N20489 002	MAY 02, 1997
	+	2.5MG/24HR	N20489 001	SEP 29, 1995

GEL; TOPICAL
ANDROGEL
+ UNIMED PHARMS 1% N21015 001 FEB 28, 2000

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

	SLO-PHYLLIN			
	@ AVENTIS	60MG	N85206 001	MAY 24, 1982
	@	125MG	N85203 001	MAY 24, 1982
	@	250MG	N85205 001	MAY 24, 1982
BC	RHONE POULENC RORER	125MG	N85203 001	MAY 24, 1982
BC		250MG	N85205 001	MAY 24, 1982
		60MG	N85206 001	MAY 24, 1982

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	BETALIN S			
AP	+ LILLY	100MG/ML	N80853 001	
	@	100MG/ML	N80853 001	
	THIAMINE HCL			
AP	AM PHARM PARTNERS	100MG/ML	N80556 001	
AP	+	100MG/ML	N80556 001	

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

	TICLOPIDINE HCL			
AB	DANBURY PHARMA	250MG	N75309 001	APR 26, 2000

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

	TIMOLOL MALEATE			
> ADD > AT	NOVEX	EQ 0.25% BASE	N75411 001	SEP 08, 2000
> ADD >				
> ADD > AT		EQ 0.5% BASE	N75412 001	SEP 08, 2000
> ADD >				

TINZAPARIN SODIUM

INJECTABLE; INJECTION

	INNOHEP			
+	DUPONT PHARMA	20,000 IU/ML	N20484 001	JUL 14, 2000

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

	ZANAFLEX			
	ELAN PHARMA	EQ 2MG BASE	N20397 002	FEB 04, 2000

TOLBUTAMIDE

TABLET; ORAL

	TOLBUTAMIDE			
AB	CHELSEA LABS	500MG	N86109 001	
AB	+	500MG	N86109 001	
AB	+ EON	500MG	N12678 001	
	@	500MG	N12678 001	

TRETINOIN

CREAM; TOPICAL

	RENOVA			
+	JOHNSON AND JOHNSON	0.02%	N21108 001	AUG 31, 2000

GEL; TOPICAL

	RETIN-A			
AB	+ JOHNSON AND JOHNSON	0.025%	N17579 002	
BT	+	0.025%	N17579 002	
	TRETINOIN			
AB	SPEAR PHARMS	0.025%	N75529 001	FEB 22, 2000

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

	FLUTEX			
AT	ZENITH GOLDLINE	0.025%	N85539 001	
AT		0.1%	N85539 002	
AT		0.5%	N85539 003	

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

	FLUTEX			
	@ ZENITH GOLDLINE	0.025%	N85539 001	
	@	0.1%	N85539 002	
	@	0.5%	N85539 003	
	TRIATEX			
AT	ZENITH GOLDLINE	0.025%	N87430 001	NOV 01, 1988
AT		0.1%	N87429 001	NOV 01, 1988
AT		0.5%	N87428 001	NOV 01, 1988
	@	0.025%	N87430 001	NOV 01, 1988
	@	0.1%	N87429 001	NOV 01, 1988
	@	0.5%	N87428 001	NOV 01, 1988

OINTMENT; TOPICAL

	ARISTOCORT A			
AT	+ FUJISAWA HLTHCARE	0.5%	N80745 003	
AT		0.5%	N80745 003	
	FLUTEX			
AT	+ ZENITH GOLDLINE	0.025%	N87375 001	NOV 01, 1988
AT	+	0.1%	N87377 001	NOV 01, 1988
AT	+	0.5%	N87376 001	NOV 01, 1988
	@	0.025%	N87375 001	NOV 01, 1988
	@	0.1%	N87377 001	NOV 01, 1988
	@	0.5%	N87376 001	NOV 01, 1988
	KENALOG			
AT	+ APOTHECON	0.025%	N11600 003	
AT		0.025%	N11600 003	
AT	+	0.1%	N11600 001	
AT		0.1%	N11600 001	
	TRIAMCINOLONE ACETONIDE			
AT	+ ALTANA	0.025%	N85691 001	
AT		0.025%	N85691 001	
AT	+	0.1%	N85691 003	
AT		0.1%	N85691 003	
AT	+	0.5%	N85691 002	

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

	TRIAMCINOLONE ACETONIDE			
AT	ALTANA	0.5%	N85691 002	
AT	CLAY PARK	0.025%	N87356 001	
AT	+	0.025%	N87356 001	
AT		0.1%	N87357 001	
AT	+	0.1%	N87357 001	
AT		0.5%	N87385 001	
AT	+	0.5%	N87385 001	

SPRAY, METERED; NASAL

	TRI-NASAL			
	+ MURO	0.05MG/SPRAY	N20120 001	FEB 04, 2000

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

	TRIFLUOPERAZINE HCL			
AB	ZENITH GOLDLINE	EQ 1MG BASE	N87612 001	NOV 19, 1982
AB		EQ 2MG BASE	N87613 001	NOV 19, 1982
AB		EQ 5MG BASE	N87328 001	NOV 19, 1982
AB		EQ 10MG BASE	N87614 001	NOV 19, 1982
	@	EQ 1MG BASE	N87612 001	NOV 19, 1982
	@	EQ 2MG BASE	N87613 001	NOV 19, 1982
	@	EQ 5MG BASE	N87328 001	NOV 19, 1982
	@	EQ 10MG BASE	N87614 001	NOV 19, 1982

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL

	TRIHEXYPHENIDYL HCL			
AA	WEST WARD	2MG	N40337 002	FEB 16, 2000
AA		5MG	N40337 001	FEB 16, 2000

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL
PRIMSOL
ASCENT PEDS — EQ 25MG BASE/5ML — N74374 001 JUN 23, 1995
\+ — EQ 25MG BASE/5ML — N74374 001 JUN 23, 1995
\+ — EQ 50MG BASE/5ML — N74973 001 JAN 24, 2000

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION
NEUTREXIN
\+ MEDIMMUNE ONCOLOGY — EQ 25MG BASE/VIAL — N20326 001 DEC 17, 1993
\+ US BIOSCIENCE — EQ 25MG BASE/VIAL — N20326 001 DEC 17, 1993 > ADD >

TRIPTORELIN PAMOATE

INJECTABLE; INJECTION
TRELSTAR DEPOT
\+ DEBIO RECHERCHE — EQ 3.75MG BASE/VIAL — N20715 001 JUN 15, 2000

TROGLITAZONE

TABLET; ORAL
PRELAY
AB SANKYO — 200MG — N20719 001 JAN 29, 1997
AB — 300MG — N20719 003 AUG 04, 1997
AB — 400MG — N20719 002 JAN 29, 1997
@ — 200MG — N20719 001 JAN 29, 1997
@ — 300MG — N20719 003 AUG 04, 1997
@ — 400MG — N20719 002 JAN 29, 1997

REZULIN
AB PARKE DAVIS PHARMS — 200MG — N20720 001 JAN 29, 1997

TROGLITAZONE

TABLET; ORAL
REZULIN
AB PARKE DAVIS PHARMS — 300MG — N20720 003 AUG 04, 1997
AB — 400MG — N20720 002 JAN 29, 1997
@ — 200MG — N20720 001 JAN 29, 1997
@ — 300MG — N20720 003 AUG 04, 1997
@ — 400MG — N20720 002 JAN 29, 1997

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
TROPICACYL
AT AKORN — 0.5% — N40314 001 SEP 29, 2000
AT — 1% — N40315 001 SEP 29, 2000

TROPICAMIDE
AT ALCON UNIVERSAL — 1% — N89172 001 DEC 28, 1990
AT MIZA PHARMS USA — 0.5% — N87636 001 JUL 30, 1982
AT — 1% — N87637 001 AUG 09, 1982
AT OPTOPICS — 0.5% — N87636 001 JUL 30, 1982
AT — 1% — N87637 001 AUG 09, 1982
AT STERIS — 1% — N89172 001 DEC 28, 1990

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC
RESCULA
\+ CIBA — 0.15% — N21214 001 AUG 03, 2000

URSODIOL

CAPSULE; ORAL

		ACTIGALL		
AB	+	NOVARTIS	300MG	N19594 002 DEC 31, 1987
	+		300MG	N19594 002 DEC 31, 1987
		URSODIOL		
AB		AMIDE PHARM	300MG	N75517 001 MAR 14, 2000
AB		COPLEY PHARM	300MG	N75592 001 MAY 25, 2000

TABLET; ORAL

		URSO		
	+	AXCAN	250MG	N20675 001 DEC 10, 1997
	+	AXCAN SCANDIPHARM	250MG	N20675 001 DEC 10, 1997

VECURONIUM BROMIDE

INJECTABLE; INJECTION

	VECURONIUM BROMIDE		
AP	BEDFORD	10MG/VIAL	N75549 001 JUN 13, 2000
AP		20MG/VIAL	N75549 002 JUN 13, 2000

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

		COVERA-HS		
BC		SEARLE	180MG	N20552 001 FEB 26, 1996
BC	+		180MG	N20552 001 FEB 26, 1996
BC			240MG	N20552 002 FEB 26, 1996
BC	+		240MG	N20552 002 FEB 26, 1996

VERTEPORFIN

INJECTABLE; INJECTION

		VISUDYNE		
	+	QLT	15MG/VIAL	N21119 001 APR 12, 2000

VITAMIN A

CAPSULE; ORAL

		VITAMIN A		
AA		GLOBAL PHARM	50,000 USP UNITS	N80952 001
	@	IMPAX LABS	50,000 USP UNITS	N80952 001

VITAMIN A PALMITATE

CAPSULE; ORAL

		VITAMIN A		
AA		GLOBAL PHARM	EQ 50,000 UNITS BASE	N80953 001
AA			EQ 50,000 UNITS BASE	N80955 001
	@	IMPAX LABS	EQ 50,000 UNITS BASE	N80953 001
	@		EQ 50,000 UNITS BASE	N80955 001

WARFARIN SODIUM

TABLET; ORAL

		WARFARIN SODIUM		
AB		INVAMED	3MG	N40196 008 JUL 26, 2000
AB			6MG	N40196 009 JUL 26, 2000

ZAFIRLUKAST

TABLET; ORAL

	ACCOLATE		
	ASTRAZENECA UK	10MG	N20547 003 SEP 17, 1999

ZOLMITRIPTAN

TABLET; ORAL

	ZOMIG		
	ASTRAZENECA PHARMS	2.5MG	N20768 001 NOV 25, 1997

ZOLMITRIPTAN

TABLET; ORAL

ZOMIG		
+ ASTRAZENECA PHARMS	5MG	N20768 002 NOV 25, 1997
ZENECA	2.5MG	N20768 001 NOV 25, 1997
+	5MG	N20768 002 NOV 25, 1997

ZONISAMIDE

CAPSULE; ORAL

ZONEGRAN		
+ DAINIPPON	100MG	N20789 001 MAR 27, 2000

ACETAMINOPHEN

TABLET, EXTENDED RELEASE; ORAL
ACETAMINOPHEN
PERRIGO 650MG N75077 001 FEB 25, 2000

ASPIRIN

TABLET, EXTENDED RELEASE; ORAL
8-HOUR BAYER
+ BAYER 650MG N16030 001
@ 650MG N16030 001
MEASURIN
+ BAYER 650MG N16030 002
@ 650MG N16030 002

BROMPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL
DIMETANE
@ WHITEHALL ROBINS 12MG N10799 011 JUN 10, 1983
DIMETAPP
+ WHITEHALL ROBINS 12MG N10799 011 JUN 10, 1983

CHLORHEXIDINE GLUCONATE

SPONGE; TOPICAL
E-Z SCRUB
BECTON DICKINSON 4% N73416 001 MAR 14, 2000

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

> DLT > SOLUTION; TOPICAL
> DLT > CHLORAPREP
> DLT > + MEDI FLEX HOSP 2%;70% N20832 001 JUL 14, 2000
> DLT >

> ADD > SPONGE; TOPICAL
> ADD > CHLORAPREP
> ADD > + MEDI FLEX HOSP 2%;70% N20832 001 JUL 14, 2000
> ADD >

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CONTAC
@ SMITHKLINE 8MG;75MG N18099 001
+ 8MG;75MG N18099 001

CIMETIDINE

TABLET; ORAL
CIMETIDINE
LEINER 200MG N74961 001 JUN 19, 1998
NOVOPHARM 200MG N74961 001 JUN 19, 1998

CLOTRIMAZOLE

CREAM; VAGINAL
TRIVAGIZOLE 3
+ TARO 2% N21143 001 APR 12, 2000

DOCOSANOL

CREAM; TOPICAL
ABREVA
> DLT > + AVANIR 10% N20941 001 JUL 25, 2000
> DLT >
> ADD > + SMITHKLINE BEECHAM 10% N20941 001 JUL 25, 2000
> ADD >

IBUPROFEN

CAPSULE; ORAL
IBUPROFEN
PHARM FORM 200MG N74782 001 JUL 06, 1998
+ 200MG N74782 001 JUL 06, 1998

TABLET; ORAL
IBUPROFEN
LEINER 200MG N74931 001 JUL 20, 1998

IBUPROFEN

TABLET; ORAL
IBUPROFEN

NOVOPHARM	200MG	N74931 001 JUL 20, 1998	> DLT > > ADD >

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL
CHILDREN'S MOTRIN COLD

+ MCNEIL CONS	100MG/5ML;15MG/5ML	N21128 001 AUG 01, 2000

LOPERAMIDE HYDROCHLORIDE

TABLET; ORAL
LOPERAMIDE HCL

LEINER	2MG	N73254 001 JUL 30, 1993
NOVOPHARM NC	2MG	N73254 001 JUL 30, 1993
PERRIGO	2MG	N75232 001 JAN 06, 2000

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC
VISINE-A

AKORN	0.025%;0.3%	N20485 001 JAN 31, 1996	> DLT > > DLT > > ADD > > ADD >
PFIZER	0.025%;0.3%	N20485 001 JAN 31, 1996	

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

LEINER	EQ 200MG BASE	N74635 001 JAN 13, 1997
NOVOPHARM NC	EQ 200MG BASE	N74635 001 JAN 13, 1997

NONOXYNOL-9

AEROSOL; VAGINAL
DELFEN

@ ORTHO	12.5%	N14349 002
@ PERSONAL PRODS	12.5%	N14349 002

PERMETHRIN

LOTION; TOPICAL
PERMETHRIN

ALPHARMA	1%	N75014 001 MAR 28, 2000

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL
RID MOUSSE

+ PFIZER	4%;EQ 0.33% BASE	N21043 001 MAR 07, 2000

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE

CHELSEA LABS	EQ 75MG BASE	N75212 001 JAN 14, 2000
CHEMINOR DRUGS	EQ 75MG BASE	N75294 001 MAR 28, 2000
GENPHARM	EQ 75MG BASE	N75497 001 JAN 14, 2000
LEINER	EQ 75MG BASE	N75094 001 JUN 21, 1999
RANBAXY	EQ 75MG BASE	N75132 001 JAN 14, 2000
	EQ 75MG BASE	N75254 001 JAN 14, 2000
TORPHARM	EQ 75MG BASE	N75167 001 MAY 04, 2000
ZENITH GOLDLINE	EQ 75MG BASE	N75296 001 JAN 14, 2000

RANITIDINE HCL

NOVOPHARM	EQ 75MG BASE	N75094 001 JUN 21, 1999

RANITIDINE HYDROCHLORIDE

TABLET, EFFERVESCENT; ORAL

ZANTAC 75			
+	GLAXO WELLCOME	EQ 75MG BASE	N20745 001 FEB 26, 1998
@	WARNER LAMBERT	EQ 75MG BASE	N20745 001 FEB 26, 1998

TERBINAFINE HYDROCHLORIDE

SOLUTION; TOPICAL

LAMISIL AT			
+	NOVARTIS	1%	N21124 001 MAR 17, 2000

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 9 SEPTEMBER '00

NO SEPTEMBER 2000 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
January through September 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine hydrogen methanesulfonate TN=	Treatment of hormone refractory prostate carcinoma.	Cell Therapeutics, Inc. 201 Elliott Avenue West Suite 400 Seattle WA 98119 DD= 1/18/00 MA=
3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one TN=	Treatment of von Hippel-Lindau disease.	Sugen, Inc. 230 East Grand Ave. South San Francisco CA 94080 DD= 3/23/00 MA=
Abetimus TN=	Treatment of lupus nephritis.	La Jolla Pharmaceutical Co. 6455 Nancy Ridge Dr. San Diego CA 92121 DD= 7/28/00 MA=
Angiotensin 1-7 TN=	Treatment of neutropenia associated with autologous bone marrow transplantation.	Maret Pharmaceuticals 4041 MacArthur Blvd. Suite 375 Newport Beach CA 92660 DD= 2/16/00 MA=

Orphan Products Designations and Approvals List
January through September 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Anti-thymocyte Globulin (Rabbitt) TN=Thymoglobulin	Treatment of myelodysplastic syndrome (MDS)	SangStat Medical Corporat 6300 Dumbarton Circle Freemont CA 94555 DD= 9/6/00 MA=
arsenic trioxide TN=Atrivex	Treatment of myelodysplastic syndrome.	Cell Therapeutics, Inc. 201 Elliott Avenue West Suite 400 Seattle WA 98119 DD= 7/17/00 MA=
Arsenic trioxide TN=Atrivex	Treatment of multiple myeloma.	Cell Therapeutics, Inc. 201 Elliott Ave. West, Suite 400 Seattle WA 98119 DD= 4/28/00 MA=
Bis(4-fluorophenyl)phenyla cetamide TN=	Treatment of sickle cell disease.	ICAgen Inc. Ion Channel Advances PO Box 14487 Durham NC 27709 DD= 3/2/00 MA=
Brimonidine TN=Alphagan	Treatment of anterior ischemic optic neuropathy.	Allergan, Inc. 2525 Dupont Dr. P.O. Box 19534 Irvine CA 92623-9534 DD= 2/7/00 MA=

Orphan Products Designations and Approvals List
January through September 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
calfactant TN=Infasurf	Acute respiratory distress syndrome (ARDS)	ONY, Inc. Baird Research Park 1576 Sweet Home Road Amherst NY 14228 DD= 9/5/00 MA=
carmustine TN=	Treatment of intracranial malignancies.	Direct Therapeutics, Inc. 1001 Bayhill Dr., Suite 100 San Bruno CA 94066 DD= 7/3/00 MA=
centruroides immune F(ab)2 TN=Alacramyn	Treatment of scorpion envenomations requiring medical attention.	Silanes Laboratories S.A. de Amores #1034 Col Del Valle C.P. 03100 Mexico D.F. DD= 6/12/00 MA=
cetuximab TN=	Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor.	ImClone Systems Incorporated Branchburg Corporate Center 22 Chubb Way Somerville NJ 08876 DD= 7/3/00 MA=
Chimeric (human-murine) G250 IgG monoclonal antibody TN=	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH Grillparzerstrasse 10B 81675 Munich Germany DE DD= 7/24/00 MA=

Orphan Products Designations and Approvals List
January through September 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Chimeric, humanized monoclonal antibody to staphylococcus TN=	Prophylaxis of Staphylococcus epidermidis sepsis in low birth weight (1500 grams or less) infants.	Biosynexus, Inc. 9610 Medical Center Drive Suite 100 Rockville MD 20850 DD= 8/3/00 MA=
Cisplatin/epinephrine TN=IntraDose	Treatment of metastatic malignant melanoma.	Matrix Pharmaceutical, In 34700 Campus Drive Fremont CA 94555-3612 DD= 9/7/00 MA=
Cisplatin/epinephrine TN=IntraDose	Treatment of squamous cell carcinoma of the head and neck.	Matrix Pharmaceutical, In 34700 Campus Drive Fremont CA 94555-3612 DD= 4/3/00 MA=
Deoxyribose, phosphorothioate TN=	Treatment of advanced malignant melanoma (Stages II,III, IV).	Genta, Inc. 99 Hayden Ave., Suite 200 Lexington MA 02421-7966 DD=7/31/00 MA=
DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2 TN=Leuvectin	Treatment of renal cell carcinoma.	Vical Incorporated 9373 Towne Center Dr. Suite 100 San Diego CA 92121-3088 DD= 4/28/00 MA=

Orphan Products Designations and Approvals List
January through September 2000

ame: eneric Name N=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
IP-Modified autologous umor vaccine N=O-Vax	Adjuvant therapy for ovarian cancer patients	AVAX Technologies, Inc. 4520 Main Street Suite 930 Kansas City MO 64111 DD= 9/21/00 MA=
c. thyl eicosapentaenoate N=	Treatment of Huntington's disease.	Laxdale Ltd. Kings Park House, Laurelhill Polmaise Road, Stirling FK7 United Kingdom UK DD= 4/6/00 MA=
c. Lucinolone N=	Treatment uveitis involving the posterior segment of the eye.	Bausch & Lomb 8500 Hidden River Parkway Tampa FL 33637 DD= 7/31/00 MA=
Luorouracil N=	Treatment of glioblastoma multiforme.	Ethypharm SA 194 Bureaux de la Colline - 92213 Saint-Cloud Cedex France FR DD= 6/29/00 MA=
G1.1-mAb N=	For patients with dermatomyositis	Alexion Pharmaceuticals, Inc. 25 Science Park Suite 360 New Haven CT 06511 DD= 9/21/00 MA=

Orphan Products Designations and Approvals List
January through September 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Halofuginone TN=Stenorol	Treatment of systemic sclerosis.	Collgard Biopharmaceutical Textile House, 2 Koifman S Tel-Aviv 68012 Israel IL DD= 2/7/00 MA=
Histamine TN=Maxamine	For use as an adjunct to cytokine therapy in the treatment of malignant melanoma.	Maxim Pharmaceuticals, Inc 8899 University Center Lan Suite 400 San Diego CA 92122 DD= 2/1/00 MA=
Hydroxycobalamin TN=CYANOKIT	Treatment of acute cyanide poisoning	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 250 Minnetonka MN 55305 DD= 9/22/00 MA=
Hypericin TN=	Treatment of glioblastoma multiforme.	Nexell Therapeutics 2751 Centerville Rd., Suit Wilmington DE 19808 DD= 8/3/00 MA=
Hypericin TN=	Treatment of cutaneous T-cell lymphoma.	Nexell Therapeutics, Inc. 2751 Centerville Rd., Suit Wilmington DE 19808 DD= 2/7/00 MA=

Orphan Products Designations and Approvals List
January through September 2000

ame: eneric Name N=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
L-4 Pseudomonas Toxin usion Protein IL-4(38-37)-PE38KDEL) N=	Treatment of astrocytic glioma.	Neurocrine Biosciences, Inc. 10555 Science Center Dr. San Diego CA 92121 DD= 4/6/00 MA=
odine I 131 is(indium-diethylenetriam nepentaacetic cid)tyrosyllysine/hMN-14 m734 F(ab')2 bispecific onoclonal antibody N=Pentacea	Treatment of small-cell lung cancer.	IBC Pharmaceuticals, L.L.C. 300 American Rd. Morris Plains NJ 07950 DD= 2/22/00 MA=
anreotide, Somatostatin N=Ipstyl	Treatment for acromegly	IPSEN, Inc. 27 Maple Street Milford MA 01757 DD= 9/11/00 MA=
evodopa and carbidopa N=Duodopa	Treatment of late stage Parkinson's disease.	Nouvel Pharma, Inc. 11322 Acuff La. Lenexa KS 66215 DD= 1/18/00 MA=
iposomal nystatin N=Nyotran	Treatment of invasive fungal infections.	Aronex Pharmaceuticals, Inc. 8707 Technology Forest Place The Woodlands TX 77381-1191 DD= 6/13/00 MA=

Orphan Products Designations and Approvals List
January through September 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Meropenem TN=Merrem IV	Management of acute pulmonary exacerbations, in cystic fibrosis patients, due to respiratory tract infection with susceptible organisms.	Zeneca Pharmaceuticals 1800 Concord Pike PO Box 15437 Wilmington DE 19850-5437 DD= 4/27/00 MA=
Natural human lymphoblastoid interferon-alpha TN=	Treatment of Behcet's disease.	Amarillo Biosciences, Inc. 800 West Ninth Avenue Amarillo TX 79101-3206 DD= 1/18/00 MA=
Natural human lymphoblastoid interferon-alpha TN=	Treatment of papillomavirus warts in the oral cavity of HIV positive patients.	Amarillo Biosciences. Inc. 800 West 9th Avenue Amarillo TX 79101 DD= 8/10/00 MA=
Omega-3 (n-3) polyunsaturated fatty acids TN=Omacor	Treatment of IgA nephropathy.	Pronova Biocare, AS PO Box 420 1327 Lysaker Norway DD= 5/4/00 MA=
Phenylbutyrate TN=	Treatment of acute promyelocytic leukemia.	Elan Corporation 1300 Gould Dr. Gainesville GA 30504 DD= 1/19/00 MA=

Orphan Products Designations and Approvals List
January through September 2000

ame: eneric Name N=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
ecombinant glycine2-human lucagon-like peptide-2 N=	Treatment of short bowel syndrome.	NPS Allelix Corp. 6850 Goreway Dr. Mississauga, Ontario L4V 1V7 Canada CA DD= 6/29/00 MA=
ecombinant human ntithrombin III N=	Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.	AT III LLC c/o Genzyme Corporation 15 Pleasant St. Connector, Framingham MA 01701 DD= 4/6/00 MA=
ecombinant human highly hosphorylated acid lpha-glucosidase N=TBD	For enzyme replacement therapy in patients with all subtypes of glycogen storage disease type II (GSDII, Pompe Disease)	Novazyme Pharmaceuticals, 800 Research Parkway Suite 200 Oklahoma City OK 73104 DD= 9/20/00 MA=
ecombinant human nsulin-like growth actor-I N=PV802	Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.	GroPep Pty Ltd. Gate 11, Victoria Dr. Adelaide SA 5000 Australia AU DD= 2/16/00 MA=
emacemide N=Ecovia	Treatment of Huntington's disease.	AstraZeneca LP 725 Chesterbrook Blvd. Wayne PA 19087-5677 DD= 3/6/00 MA=

Orphan Products Designations and Approvals List
January through September 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
rSP-C lung surfactant TN=Venticute	Treatment of adult respiratory distress syndrome.	Byk Gulden Pharmaceutical Byk-Gulden StraBe 2 78467 Konstanz Germany DE DD= 4/3/00 MA=
Soluble complement receptor type 1 TN=	Prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass.	Avant Immunotherapeutics, 119 Fourth Ave. Needham MA 02494-2725 DD= 3/6/00 MA=
Synthetic human secretin TN=	For use in conjunction with diagnostic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4 DD= 3/7/00 MA=
Synthetic porcine secretin TN=	For use in conjunction with diagnostic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4 DD= 3/7/00 MA=
Technetium Tc 99m pterotetramide TN=	For the identification of ovarian carcinomas.	Endocyte, Inc. 1205 Kent Ave. Lafayette IN 47906 DD= 2/16/00 MA=

Orphan Products Designations and Approvals List
January through September 2000

ame: eneric Name N=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approva
etraiodothyroacetic acid N=	Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.	Danforth, Jr., MD, Elliot University of Vermont 84 Beartown Rd. Underhill VT 05489 DD= 5/1/00 MA=
hymalfasin N=Zadaxin	Treatment of hepatocellular carcinoma.	SciClone Pharmaceuticals, 901 Mariner's Blvd., Suite San Mateo CA 94404 DD= 3/6/00 MA=
rimetrexate N=Neutrexin	Treatment of metastatic osteogenic sarcoma.	Medimmune Oncology, Inc. One Tower Bridge 100 Front St., Suite 400 West Conshohocken PA 19428 DD= 8/10/00 MA=
apreotide N=Octastatin	Treatment of esophageal variceal hemorrhage patients with portal hypertension.	Debiopharm S.A. 17 rue des Terreaux CH-1000 Lausanne 9 Switzerland CH DD= 1/10/00 MA=
apreotide N=Octastatin	Treatment of gastrointestinal and pancreatic fistulas.	Debiopharm S.A. 17 rue des Terreaux CH-1000 Lausanne 9 Switzerland CH DD= 1/10/00 MA=

Orphan Products Designations and Approvals List
January through September 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Vapreotide TN=Octastatin	Prevention of early postoperative complications following pancreatic resection.	Debiopharm S.A. 17, rue des Terreaux CH-1000 Lausanne 9 Switzerland CH DD= 3/6/00 MA=
vigabatrin TN=Sabril	Treatment of infantile spasms.	Aventis Pharmaceuticals In P.O. Box 9627 Kansas City MO 64137 DD= 6/12/00 MA=
Zoledronate TN=Zometa, Zabel	Treatment of tumor induced hypercalcemia.	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-108 DD= 8/18/00 MA=

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO SEPTEMBER 2000 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	075077 001	ACETAMINOPHEN;ACETAMINOPHEN				PC	NOV 12, 2000
	020338 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010			
	020380 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010			
	020748 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010		NCE	MAY 31, 2001
			RE34440	MAY 31, 2010	U-275	NDF	MAY 26, 2003
	020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6080756	JUL 05, 2016			
	020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6080756	JUL 05, 2016			
	020560 001	ALENDRONATE SODIUM;FOSAMAX	6008207	JUN 06, 2015	U-303	M-3	NOV 24, 2002
>ADD>			6090410	DEC 02, 2012		I-309	SEP 29, 2003
	020560 002	ALENDRONATE SODIUM;FOSAMAX	6008207	JUN 06, 2015	U-303	M-3	NOV 24, 2002
			6090410	DEC 02, 2012			
	020560 003	ALENDRONATE SODIUM;FOSAMAX	6008207	JUN 06, 2015	U-303	M-3	NOV 24, 2002
			6090410	DEC 02, 2012			
>ADD>	020560 004	ALENDRONATE SODIUM;FOSAMAX	6015801	JUL 17, 2018	U-353	NS	OCT 20, 2000
>ADD>			4621077	AUG 06, 2007	U-114	D-61	OCT 20, 2003
>ADD>			5358941	DEC 02, 2012		D-62	OCT 20, 2003
>ADD>			5681590	DEC 02, 2012			
>ADD>			5804570	FEB 17, 2015			
>ADD>			5849726	JUN 06, 2015			
>ADD>			5944329	JUL 17, 2018			
>ADD>			6008207	JUN 06, 2015			
>ADD>	020560 005	ALENDRONATE SODIUM;FOSAMAX	6015801	JUL 17, 2018	U-353	NS	OCT 20, 2003
>ADD>			4621077	AUG 06, 2007	U-114	D-61	OCT 20, 2003
>ADD>			5358941	DEC 02, 2012		D-62	OCT 20, 2003
>ADD>			5681590	DEC 02, 2012			
>ADD>			5804570	FEB 17, 2015			
>ADD>			5849726	JUN 06, 2015			
>ADD>			5994329	JUL 17, 2018			
>ADD>			6008207	JUN 06, 2015			
	021107 001	ALOSETRON HYDROCHLORIDE;LOTRONEX				NCE	FEB 09, 2005
	018276 001	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
	018276 002	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
	018276 003	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
	018276 004	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
	020221 001	AMIFOSTINE;ETHYOL				I-283	JUN 24, 2002
	020221 002	AMIFOSTINE;ETHYOL				I-283	JUN 24, 2002
	021007 001	AMPRENAVIR;AGENERASE	5723490	MAR 03, 2013	U-257		
			5646180	JUL 08, 2014	U-257		
			5585397	DEC 17, 2013			
	021007 002	AMPRENAVIR;AGENERASE	5723490	MAR 03, 2015	U-257		
			5646180	JUL 08, 2014	U-257		
			5585397	DEC 17, 2013			
	021039 001	AMPRENAVIR;AGENERASE	5723490	MAR 03, 2015	U-257		
			5646180	JUL 08, 2014	U-257		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020541 001	ANASTROZOLE;ARIMIDEX	RE36617	DEC 27, 2009			
	020883 001	ARGATROBAN;ACOVA				NCE	JUN 30, 2005
>ADD>	021248 001	ARSENIC TRIOXIDE;TRISENOX				ODE	SEP 25, 2007
>ADD>						NCE	SEP 25, 2005
	020971 001	ARTICAINE HYDROCHLORIDE;SEPTOCAINE				NC	APR 03, 2003
	021127 001	AZELASTINE HYDROCHLORIDE;OPTIVAR	5164194	NOV 01, 2010		NCE	NOV 01, 2001
			5164194*	MAY 01, 2011		NDF	MAY 22, 2003
						PED	MAY 01, 2002
	020610 001	BALSALAZIDE DISODIUM;COLAZAL	4412992	JUL 08, 2001		PED	NOV 22, 2003
	021055 001	BEXAROTENE;TARGRETIN				NCE	JUL 18, 2005
	021056 001	BEXAROTENE;TARGRETIN				ODE	DEC 29, 2006
>ADD>						NCE	DEC 29, 2004
	019982 001	BISOPROLOL FUMARATE;ZEBETA				NDF	JUN 28, 2003
			4258062	MAR 24, 2000	U-63		
	019982 002	BISOPROLOL FUMARATE;ZEBETA	4258062*PED	SEP 24, 2000	U-63		
			4258062	MAR 24, 2000	U-63		
	020186 001	BISOPROLOL FUMARATE;ZIAC	4258062*PED	SEP 24, 2000	U-63		
			4258062	MAR 24, 2000	U-63		
	020186 002	BISOPROLOL FUMARATE;ZIAC	4258062*PED	SEP 24, 2000	U-63		
			4258062	MAR 24, 2000	U-63		
	020186 003	BISOPROLOL FUMARATE;ZIAC	4258062*PED	SEP 24, 2000	U-63		
			4258062	MAR 24, 2000	U-63		
			4358062*PED	SEP 24, 2000	U-63		
	050443 002	BLEOMYCIN SULFATE;BLENOXANE				ODE	FEB 20, 2003
	020929 001	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
	020929 002	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
	020711 002	BUPROPION HYDROCHLORIDE;ZYBAN				D-54	SEP 10, 2002
	020711 003	BUPROPION HYDROCHLORIDE;ZYBAN				D-54	SEP 10, 2002
	018731 001	BUSPIRONE HYDROCHLORIDE;BUSPAR	4182763	MAY 22, 2000	U-13		
			5015646	MAY 14, 2008			
			4182763*PED	NOV 22, 2000	U-13		
	018731 002	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646*PED	NOV 14, 2008			
			4182763	MAY 22, 2000	U-13		
			5015646	MAY 14, 2008			
	018731 003	BUSPIRONE HYDROCHLORIDE;BUSPAR	4182763*PED	NOV 22, 2000	U-13		
			5015646*PED	NOV 14, 2008			
			5015646	MAY 14, 2008			
	018731 004	BUSPIRONE HYDROCHLORIDE;BUSPAR	4182763	MAY 22, 2000	U-13		
			4182763*PED	NOV 22, 2000	U-13		
			5015646*PED	NOV 14, 2008			
			4182763	MAY 22, 2000	U-13		
			5015646	MAY 14, 2008			
			4182763*PED	NOV 22, 2000			
			5015646*PED	NOV 14, 2008	U-13		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020793 001	CAFFEINE CITRATE;CAFCIT				ODE	SEP 21, 2006
>ADD>	020313 002	CALCITONIN, SALMON;MIACALCIN	5759565	MAR 31, 2015			
	018874 001	CALCITRIOL;CALCIJEX	6051567	AUG 02, 2019			
	018874 002	CALCITRIOL;CALCIJEX	6051567	AUG 02, 2019			
>ADD>	020958 001	CALCIUM CARBONATE, PRECIPITATED;PEPCID COMPLETE	5229137	MAY 06, 2012	U-349	NC	OCT 15, 2003
	021093 001	CANDESARTAN CILEXETIL;ATACAND HCT	5705517	APR 18, 2011	U-3	NCE	JUN 04, 2003
			5721263	FEB 24, 2015	U-3	NC	SEP 05, 2003
			5958961	JUN 06, 2014	U-3		
			5196444	APR 18, 2011	U-3		
			5534534	JUL 09, 2013			
			5703110	APR 18, 2011	U-3		
	021093 002	CANDESARTAN CILEXETIL;ATACAND HCT	5705517	APR 18, 2011	U-3	NCE	JUN 04, 2003
			5721263	FEB 24, 2015	U-3	NC	SEP 05, 2003
			5958961	JUN 06, 2014	U-3		
			5196444	APR 18, 2011	U-3		
			5534534	JUL 09, 2013			
			5703110	APR 18, 2011	U-3		
	020896 001	CAPECITABINE;XELODA	4966891	JAN 13, 2011	U-272		
	020896 002	CAPECITABINE;XELODA	4966891	JAN 13, 2011	U-272		
	020297 001	CARVEDILOL;COREG	5902821	FEB 07, 2016	U-313		
	020297 002	CARVEDILOL;COREG	5902821	FEB 07, 2016	U-313		
	020297 003	CARVEDILOL;COREG	5902821	FEB 07, 2016	U-313		
	020297 004	CARVEDILOL;COREG	5902821	FEB 07, 2016	U-313		
	020740 001	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
						I-303	JUL 21, 2003
	020740 002	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
						I-303	JUL 21, 2003
	020740 003	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
						I-303	JUL 21, 2003
	020740 004	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
						I-303	JUL 21, 2003
	020740 005	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
						I-303	JUL 21, 2003
	020740 006	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		D-59	JUL 21, 2003
			5177080	JAN 26, 2011		I-303	JUL 21, 2003
						NS	JUL 21, 2003
	021197 001	CETRORELIX;CETROTIDE	4800191	JUL 17, 2007		NCE	AUG 11, 2005
			5198533	JUL 17, 2007			
	021197 002	CETRORELIX;CETROTIDE	4800191	JUL 17, 2007		NCE	AUG 11, 2005
			5198533	JUL 17, 2007			
	020989 002	CEVIMELINE HYDROCHLORIDE;EVOXAC	4855290	AUG 08, 2006		NCE	JAN 11, 2005
			5340821	AUG 23, 2011	U-309		
			5580880	JUN 06, 2015	U-310		
	020832 001	CHLORHEXIDINE GLUCONATE;CHLORAPREP				NC	JUL 14, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020822 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
	021046 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
	021142 001	CLOBETASOL PROPIONATE;OLUX FOAM				NDF	MAY 26, 2003
	021143 001	CLOTRIMAZOLE;TRIVAGIZOLE 3				NP	NOV 24, 2001
	021141 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	5624963	APR 29, 2014	U-323	NCE	MAY 26, 2005
			5679717	APR 29, 2014	U-323		
			5693675	DEC 02, 2014			
			5607669	JUN 10, 2014	U-323		
			5917007	APR 29, 2014	U-323		
			5919832	JUN 10, 2014			
	021176 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	5919832	JUN 10, 2014		NCE	MAY 26, 2005
			5917007	APR 29, 2014	U-323		
			5607669	JUN 10, 2014	U-323		
			5693675	DEC 02, 2014			
			5679717	APR 29, 2014	U-323		
			5624963	APR 29, 2014	U-323		
	020287 001	DALTEPARIN SODIUM;FRAGMIN				D-60	AUG 03, 2003
	020287 003	DALTEPARIN SODIUM;FRAGMIN				D-60	AUG 03, 2003
	020287 004	DALTEPARIN SODIUM;FRAGMIN				D-60	AUG 03, 2003
>ADD>	020713 001	DESOGESTREL;MIRCETTE	RE35724	OCT 20, 2008			
	020212 001	DEXRAZOXANE HYDROCHLORIDE;ZINECARD	5242901	SEP 07, 2010	U-339		
			4963551	DEC 21, 2007			
			4275063	JUN 23, 2003			
	020212 002	DEXRAZOXANE HYDROCHLORIDE;ZINECARD	5242901	SEP 07, 2010	U-339		
			4963551	DEC 21, 2007			
			4275063	JUN 23, 2003			
	020154 002	DIDANOSINE;VIDEX				D-58	OCT 28, 2002
	020154 003	DIDANOSINE;VIDEX				D-58	OCT 28, 2002
	020154 004	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180	D-58	OCT 28, 2002
	020154 005	DIDANOSINE;VIDEX				D-58	OCT 28, 2002
	020154 006	DIDANOSINE;VIDEX				NS	OCT 28, 2002
						D-58	OCT 28, 2002
	020939 001	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
			5529791	JUN 25, 2013			
	020939 002	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
			5529791	JUN 25, 2013			
	020939 003	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
			5529791	JUN 25, 2013			
	020939 004	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
			5529791	JUN 25, 2013			
	021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	4988731	JAN 29, 2008		NP	AUG 04, 2003
			4913906	APR 03, 2007			
	020941 001	DOCOSANOL;ABREVA				NCE	JUL 25, 2005
>ADD>	020931 001	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020931 002	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018			
>ADD>	020931 003	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018			
	020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906775	MAR 06, 2007			
	020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906775	MAR 06, 2007			
	020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906775	MAR 06, 2007			
	020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	4797413	APR 28, 2008	U-103		
			4619939	OCT 28, 2003	U-104		
	021027 001	DOXERCALCIFEROL;HECTOROL	5602116	APR 03, 2115	U-321	NDF	APR 06, 2003
			5707980	FEB 11, 2117	U-321	NCE	JUN 09, 2004
	021145 001	EFLORNITHINE HYDROCHLORIDE;VANIQA	4413141	NOV 01, 2000		NP	JUL 27, 2003
			4720489	JAN 19, 2005	U-334		
			5648394	JUL 15, 2014	U-334		
	019221 001	ENALAPRIL MALEATE;VASERETIC	4472380	SEP 18, 2001			
			4374829	FEB 22, 2000			
			4374829*PED	AUG 22, 2000			
			4472380*PED	MAR 18, 2002			
	019221 003	ENALAPRIL MALEATE;VASERETIC	4472380	SEP 18, 2001			
			4374829	FEB 22, 2000			
			4374829*PED	AUG 22, 2000			
			4472380*PED	MAR 18, 2002			
	018998 001	ENALAPRIL MALEATE;VASOTEC	4374829	FEB 22, 2000			
			4374829*PED	AUG 22, 2000			
	018998 002	ENALAPRIL MALEATE;VASOTEC	4374829	FEB 22, 2000			
			4374829*PED	AUG 22, 2000			
	018998 003	ENALAPRIL MALEATE;VASOTEC	4374829	FEB 22, 2000			
			4374829*PED	AUG 22, 2000			
	018998 005	ENALAPRIL MALEATE;VASOTEC	4374829	FEB 22, 2000			
			4374829*PED	AUG 22, 2000			
	019309 001	ENALAPRILAT;VASOTEC	4374829	FEB 22, 2000			
			4374829*PED	AUG 22, 2000			
	020444 001	EPOPROSTENOL SODIUM;FLOLAN				ODE	APR 14, 2007
						I-296	APR 14, 2003
	020444 002	EPOPROSTENOL SODIUM;FLOLAN				ODE	APR 14, 2007
						I-296	APR 14, 2003
>ADD>	020874 001	ESTRADIOL CYPIONATE;LUNELLE				NP	OCT 05, 2003
	020907 001	ESTRADIOL;ACTIVELLE				I-295	APR 11, 2003
	020655 001	ESTRADIOL;ALORA	5122383	MAY 17, 2011			
			5227169	MAY 17, 2011			
			5212199	MAY 17, 2011			
			5164190	DEC 11, 2010			
	020655 002	ESTRADIOL;ALORA	5122383	MAY 17, 2011			
			5227169	MAY 17, 2011			
			5212199	MAY 17, 2011			
			5164190	DEC 11, 2010			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020655 003	ESTRADIOL;ALORA	5122383	MAY 17, 2011			
			5227169	MAY 17, 2011			
			5212199	MAY 17, 2011			
			5164190	DEC 11, 2010			
	021040 001	ESTRADIOL;ORTHO-PREFEST	5108995	APR 28, 2009	U-311		
			5382573	JAN 17, 2012			
	020323 001	ESTRADIOL;VIVELLE				I-254	AUG 16, 2003
	020323 002	ESTRADIOL;VIVELLE				I-254	AUG 16, 2003
	020323 003	ESTRADIOL;VIVELLE				I-254	AUG 16, 2003
	020323 004	ESTRADIOL;VIVELLE				I-254	AUG 16, 2003
	020323 005	ESTRADIOL;VIVELLE	4994278	MAR 04, 2008		NS	AUG 16, 2003
			5300291	APR 05, 2011		I-254	AUG 16, 2003
			4814168	MAR 04, 2008			
			4994267	MAR 04, 2008			
	075696 001	ETODOLAC;ETODOLAC				PC	FEB 04, 2001
	020584 001	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008			
			4966768	OCT 30, 2007			
	020584 002	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008			
			4966768	OCT 30, 2007			
	020584 003	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008			
			4966768	OCT 30, 2007			
	019304 002	FENOFIBRATE;TRICOR (MICRONIZED)				I-298	APR 24, 2003
	019304 003	FENOFIBRATE;TRICOR (MICRONIZED)				I-298	APR 24, 2003
	019304 004	FENOFIBRATE;TRICOR (MICRONIZED)				I-298	APR 24, 2003
	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6037353	MAR 14, 2017	U-138		
			6113942	FEB 28, 2015			
	020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
>ADD>			5932247	FEB 28, 2015		NCE	JUL 25, 2001
			5855912	FEB 28, 2015			
			4254129	FEB 17, 2001	U-139		
			6037353	MAR 14, 2017	U-138		
			6113942	FEB 28, 2015			
	020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
>ADD>			5932247	FEB 28, 2015		NCE	JUL 25, 2001
			5855912	FEB 28, 2015			
			4254129	FEB 17, 2001	U-139		
			6037353	MAR 14, 2017	U-138		
			6113942	FEB 28, 2015			
	020872 004	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
>ADD>			5932247	FEB 28, 2015		NCE	JUL 25, 2001
			5855912	FEB 28, 2015			
			4254129	FEB 17, 2001	U-139		
			6037353	MAR 14, 2017	U-138		
			6113942	FEB 28, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	6037353	MAR 14, 2017	U-138		
			6039974	JUL 31, 2018			
			6113942	FEB 28, 2015			
	019949 004	FLUCONAZOLE;DIFLUCAN	4416682	JUN 02, 2001			
			4404216	JAN 29, 2004			
	018936 007	FLUOXETINE HYDROCHLORIDE;SARAFEM	4971998	NOV 20, 2007	U-338	NP	JUL 06, 2003
			5114976	MAY 19, 2009	U-341		
			5744501	MAY 19, 2009	U-342		
	018936 008	FLUOXETINE HYDROCHLORIDE;SARAFEM	4971998	NOV 20, 2007	U-338	NP	JUL 06, 2003
			5114976	MAY 19, 2009	U-341		
			5744501	MAY 19, 2009	U-342		
	021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50				NC	AUG 24, 2003
	021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50				NC	AUG 24, 2003
	021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50				NC	AUG 24, 2003
	020378 001	FOLLITROPIN ALFA/BETA;GONAL-F				ODE	MAY 24, 2007
						I-306	MAY 24, 2003
	020378 002	FOLLITROPIN ALFA/BETA;GONAL-F				ODE	MAY 24, 2007
						I-306	MAY 24, 2003
>ADD>	020378 003	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242	I-306	MAY 24, 2003
>ADD>			5767251	JUN 16, 2015		ODE	MAY 24, 2007
	020235 001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-86	PED	MAR 29, 2002
			5084479	JAN 02, 2010	U-125	D-43	SEP 29, 2001
			4894476*PED	NOV 02, 2008			
			4087544*PED	JUL 16, 2000	U-86		
			5084479*PED	JUL 02, 2010	U-125		
			4894476	MAY 02, 2008			
			6054482	APR 25, 2017			
			6054482*PED	OCT 25, 2017			
	020235 002	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		PED	MAR 29, 2002
			5084479	JAN 02, 2010	U-125	D-43	SEP 29, 2001
			4087544	JAN 16, 2000	U-86		
			5084479*PED	JUL 02, 2010	U-125		
			4894476*PED	NOV 02, 2008			
			4087544*PED	JUL 16, 2000	U-86		
			6054482	APR 25, 2017			
			6054482*PED	OCT 25, 2017			
	020235 003	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-86	PED	MAR 29, 2002
			5084479	JAN 02, 2010	U-125	D-43	SEP 29, 2001
			4894476	MAY 02, 2008			
			4087544*PED	JUL 16, 2000	U-86		
			5084479*PED	JUL 02, 2010			
			4894476*PED	NOV 02, 2008			
			6054482	APR 25, 2017			
			6054482*PED	OCT 25, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020882 001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106		
			4894476	MAY 02, 2008			
			5084479	JAN 02, 2010	U-258		
			5084479*PED	JUL 02, 2010	U-258		
			4087544*PED	JUL 16, 2000	U-106		
			4894476*PED	NOV 02, 2008			
			6054482	APR 25, 2017			
			6054482*PED	OCT 25, 2017			
	020882 002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106		
			4894476	MAY 02, 2008			
			5084479	JAN 02, 2010	U-258		
			4087544*PED	JUL 16, 2000	U-106		
			4894476*PED	NOV 02, 2008			
			5084479*PED	JUL 02, 2010	U-258		
			6054482	APR 25, 2017			
			6054482*PED	OCT 25, 2017			
	021037 001	GADOPENTETATE DIMEGLUMINE;MAGNEVIST	5362475	NOV 08, 2011			
			5560903	OCT 01, 2013			
			4647447	MAR 03, 2004			
			4957939	MAR 03, 2004			
			4963344	MAR 03, 2004			
	020460 002	GANCICLOVIR;CYTOVENE	4507305	MAY 21, 2001	U-64		
			4423050	MAY 21, 2001	U-64		
			4355032	JUN 23, 2003	U-64		
			4642346	JUN 24, 2005			
	021174 001	GEMTUZUMAB OZOGAMICIN;MYLOTARG	5606040	FEB 25, 2014		ODE	MAY 17, 2007
			5693762	DEC 02, 2014		NCE	MAY 17, 2005
			5739116	APR 14, 2015			
			5767285	JUN 16, 2015			
			5773001	JUN 30, 2015	U-320		
			4970198	NOV 30, 2007			
			5079233	JAN 07, 2009			
			5585089	DEC 17, 2013			
	020622 001	GLATIRAMER ACETATE;COPAXONE	5981589	MAY 24, 2014			
			6054430	MAY 24, 2014			
	021178 001	GLYBURIDE;GLUCOVANCE				NC	JUL 31, 2003
	021178 002	GLYBURIDE;GLUCOVANCE				NC	JUL 31, 2003
	021178 003	GLYBURIDE;GLUCOVANCE				NC	JUL 31, 2003
>ADD>	021149 002	GONADOTROPIN CHORIONIC RECOMBINANT HUMAN;OVIDREL	5767251	JUN 16, 2015		NP	SEP 20, 2003
	020125 001	HYDROCHLOROTHIAZIDE;ACCURETIC				NC	DEC 28, 2002
	020125 002	HYDROCHLOROTHIAZIDE;ACCURETIC				NC	DEC 28, 2002
	020125 003	HYDROCHLOROTHIAZIDE;ACCURETIC				NC	DEC 28, 2002
>ADD>	020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	5138069	AUG 11, 2009			
>ADD>			5153197	OCT 06, 2009	U-3		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019778 001	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001			
019778 002	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001			
019778 003	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001	U-3		
019771 001	IBUPROFEN;ADVIL COLD AND SINUS	4552899	APR 09, 2004			
		4552899*PED	OCT 09, 2004			
019763 003	IFOSFAMIDE;IFEX/MESNEX KIT	4220660	MAR 06, 2001	U-21		
		5696172	OCT 06, 2013			
019763 004	IFOSFAMIDE;IFEX/MESNEX KIT	4220660	MAR 06, 2001	U-21		
		5696172	OCT 06, 2013			
020986 001	INSULIN ASPART RECOMBINANT;NOVOLOG				NCE	JUN 07, 2005
					PED	OCT 20, 2005
021081 001	INSULIN GLARGINE;LANTUS				NCE	APR 20, 2005
					D-56	APR 04, 2003
020563 001	INSULIN LISPRO;HUMALOG				NC	DEC 22, 2002
021018 001	INSULIN LISPRO;HUMALOG MIX 50/50				D-56	APR 04, 2003
020563 002	INSULIN LISPRO;HUMALOG PEN	5474978	JUN 16, 2014			
		5514646	MAY 07, 2013	U-111	NCE	JUN 14, 2001
					I-299	APR 20, 2003
020571 001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR	4727064	FEB 23, 2005			
020966 001	ITRACONAZOLE;SPORANOX	4942162	FEB 11, 2003			
019084 001	KETOCONAZOLE;NIZORAL	4828838*PED	MAR 17, 2006		NCE	NOV 17, 2000
020857 001	LAMIVUDINE;COMBIVIR	4833130*PED	MAR 17, 2006		PED	MAY 17, 2001
		4837208	SEP 17, 2005			
		5047407*PED	AUG 08, 2009			
		4724232*PED	MAR 17, 2006			
		4818538*PED	MAR 17, 2006			
		5859021*PED	NOV 15, 2012	U-248		
		5905082*PED	NOV 18, 2016	U-248		
		6113920	OCT 23, 2017	U-257		
		6113920*PED	APR 23, 2018	U-257		
		4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4828838	SEP 17, 2005			
		4833130	SEP 17, 2005			
		5047407	FEB 08, 2009			
		5859021	MAY 15, 2012	U-248		
		5905082	MAY 18, 2016	U-248		
		4837208*PED	MAR 17, 2006			
020564 001	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009		NCE	NOV 17, 2000
		5905082	MAY 18, 2016		PED	MAY 17, 2001
		5905082*PED	NOV 18, 2016			
		5047407*PED	MAY 17, 2010			
020596 001	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009		NCE	NOV 17, 2000
		6004968	MAR 20, 2018		PED	MAY 17, 2001
		6004968*PED	SEP 20, 2018			
		5047407*PED	MAY 17, 2010			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021003 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		I-257	DEC 08, 2001
			5532246	JUL 02, 2013	U-250	PED	JUN 08, 2002
			5905082	MAY 18, 2016			
			5047407*PED	AUG 08, 2009			
			5532246*PED	JAN 02, 2014	U-250		
			5905082*PED	NOV 18, 2016			
	021004 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		NCE	NOV 17, 2000
			5532246	JUL 02, 2013	U-250	I-257	DEC 08, 2001
			6004968	MAR 20, 2018		PED	MAY 17, 2001
			5047407*PED	AUG 08, 2009		PED	JUN 08, 2002
			5532246*PED	JAN 02, 2014	U-250		
			6004968*PED	SEP 20, 2018			
>ADD>	021088 001	LEUPROLIDE ACETATE;VIADUR	6113938	JUL 24, 2018		NP	MAR 03, 2003
>ADD>			6124261	JUN 13, 2017			
			5728396	JAN 30, 2017	U-316		
			5932547	JUN 13, 2017			
			5985305	JAN 30, 2017			
	020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U-332		
			5547994	AUG 20, 2013	U-332		
			5760090	JAN 05, 2010	U-332		
			5844002	JAN 05, 2010	U-332		
	020837 002	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U-332		
			5547994	AUG 20, 2013	U-332		
			5760090	JAN 05, 2010	U-332		
			5844002	JAN 05, 2010	U-332		
	021114 001	LEVOBETAXOLOL HYDROCHLORIDE;BETAXON				NP	FEB 23, 2003
	020634 001	LEVOFLOXACIN;LEVAQUIN				I-305	FEB 02, 2003
	020634 002	LEVOFLOXACIN;LEVAQUIN				I-305	FEB 02, 2003
	020635 001	LEVOFLOXACIN;LEVAQUIN				I-305	FEB 02, 2003
	020635 002	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE				I-305	FEB 02, 2003
	020635 003	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE				I-305	FEB 02, 2003
>ADD>	021199 001	LEVOFLOXACIN;QUIXIN	5053407	OCT 01, 2008		NDF	AUG 18, 2003
			4382892	SEP 02, 2003			
			5503407	OCT 01, 2008			
			4551456	NOV 14, 2003			
	020612 001	LIDOCAINE;LIDODERM				NP	MAR 19, 2002
	021130 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
	021130 002	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
	021131 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
	021132 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
	019558 001	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
	019558 002	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
	019558 003	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
	019558 004	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019558 006	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
	019777 001	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
	019777 002	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
	019777 003	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
	019777 004	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
	019777 005	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
	019777 006	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
>ADD>	021226 001	LOPINAVIR;KALETRA	5914332	DEC 13, 2015	U-351		
>ADD>			5635523	JUN 30, 2014	U-352		
>ADD>			5541206	JUL 30, 2013	U-348		
>ADD>			5674882	OCT 07, 2014	U-344		
>ADD>			5886036	DEC 29, 2012	U-345		
>ADD>			6037157	JUN 26, 2016	U-346		
>ADD>			5846987	DEC 29, 2012	U-350		
>ADD>			5648497	JUL 15, 2014			
>ADD>	021251 001	LOPINAVIR;KALETRA	5541206	JUL 30, 2013	U-348		
>ADD>			5914332	DEC 13, 2005	U-351		
>ADD>			5635523	JUN 03, 2014	U-352		
>ADD>			5846987	DEC 29, 2012	U-350		
>ADD>			5648497	JUL 15, 2014			
>ADD>			5674882	OCT 07, 2014	U-344		
>ADD>			5886036	DEC 29, 2012	U-345		
>ADD>			6037157	JUN 26, 2016	U-346		
	019658 001	LORATADINE;CLARITIN	4282233	JUN 19, 2002	U-77		
			4659716	APR 21, 2004	U-142		
			4863931	SEP 15, 2008			
			4282233*PED	DEC 19, 2002	U-77		
			4659716*PED	OCT 21, 2004	U-142		
			4863931*PED	MAR 15, 2009			
>ADD>	020641 001	LORATADINE;CLARITIN	6132758	JUN 01, 2018			
			4659716	APR 21, 2004	U-142		
			4282233	JUN 19, 2002	U-77		
			4863931	SEP 15, 2008			
			4659716*PED	OCT 21, 2004	U-142		
			4863931*PED	MAR 15, 2009			
			4282233*PED	DEC 19, 2002	U-77		
	020704 001	LORATADINE;CLARITIN REDITABS	4659716	APR 21, 2004	U-142		
			4282233	JUN 19, 2002	U-77		
			4371516	FEB 01, 2000			
			4863931	SEP 15, 2008			
			4659716*PED	OCT 21, 2004	U-142		
			4282233*PED	DEC 19, 2002	U-77		
			4371516*PED	AUG 01, 2000			
			4863931*PED	MAR 15, 2009			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019670 001	LORATADINE;CLARITIN-D	4282233	JUN 19, 2002	U-77		
			4659716	APR 21, 2004	U-142		
			4863931	SEP 15, 2008			
			4282233*PED	DEC 19, 2002	U-77		
			4659716*PED	OCT 21, 2004	U-142		
			4863931*PED	MAR 15, 2009			
	020470 001	LORATADINE;CLARITIN-D 24 HOUR	4659716	APR 21, 2004	U-142		
			4282233	JUN 19, 2002	U-77		
			5314697*PED	APR 23, 2013			
			4863931	SEP 15, 2008			
			4659716*PED	OCT 21, 2004	U-142		
			4282233*PED	DEC 19, 2002	U-77		
			4863931*PED	MAR 15, 2009			
	020803 001	LOTEPREDNOL ETABONATE;ALREX	5314697	APR 23, 2013			
	020583 001	LOTEPREDNOL ETABONATE;LOTEMAX	4966335	MAR 09, 2012			
	020938 001	MELOXICAM;MOBIC	4966335	MAR 09, 2012			
	020049 001	MESALAMINE;PENTASA				NCE	APR 13, 2005
	019884 001	MESNA;MESNEX	4980173	JAN 29, 2002	U-78		
	020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE	5696172	OCT 06, 2013			
						PED	SEP 03, 2000
						NCE	MAR 03, 2000
						I-307	OCT 22, 2001
	020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	APR 22, 2002
						PED	SEP 03, 2000
						NCE	MAR 03, 2000
						I-307	OCT 22, 2001
	020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	APR 22, 2002
						NCE	MAR 03, 2000
						I-307	OCT 22, 2001
						PED	SEP 03, 2000
	020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	APR 22, 2002
						NCE	MAR 03, 2000
						I-307	OCT 22, 2001
						PED	SEP 03, 2000
	020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	APR 22, 2002
						PED	SEP 03, 2000
						NCE	MAR 03, 2000
						I-307	OCT 22, 2001
	021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA				PED	APR 22, 2002
	021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA				NP	AUG 01, 2003
	019815 001	MIDODRINE HYDROCHLORIDE;PROAMATINE				NP	AUG 01, 2003
	019815 002	MIDODRINE HYDROCHLORIDE;PROAMATINE				ODE	SEP 06, 2003
>ADD>	020687 001	MIFEPRISTONE;MIFEPREX				ODE	SEP 06, 2003
>ADD>			4386085	JAN 08, 2002		NCE	SEP 28, 2005
>ADD>			4447424	JAN 08, 2002			
			4626531	OCT 12, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	6127353	OCT 03, 2017			
	020830 002	MONTELUKAST SODIUM;SINGULAIR	5565473	NOV 30, 2010	U-228	I-300	MAR 03, 2003
						NS	MAR 03, 2003
						NCE	FEB 20, 2003
	019516 001	MORPHINE SULFATE;MS CONTIN	4366310	DEC 10, 2000			
	019516 002	MORPHINE SULFATE;MS CONTIN	4366310	DEC 10, 2000			
	019516 003	MORPHINE SULFATE;MS CONTIN	4366310	DEC 10, 2000			
	019516 004	MORPHINE SULFATE;MS CONTIN	4366310	DEC 10, 2000			
	019516 005	MORPHINE SULFATE;MS CONTIN	4366310	DEC 10, 2000			
	020152 001	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
	020152 002	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
	020152 003	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
	020152 004	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
	020152 005	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
	020152 006	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
	020381 001	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
	020381 002	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
	020381 003	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
	020381 004	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
	020381 005	NIACIN;NIASPAN TITRATION ST	6080428	MAY 27, 2017	U-331		
>ADD>	020076 001	NICOTINE;HABITROL	5834011	MAY 01, 2007			
>ADD>	020076 002	NICOTINE;HABITROL	5834011	MAY 01, 2007			
>ADD>	020076 003	NICOTINE;HABITROL	5834011	MAY 01, 2007			
>ADD>	020076 004	NICOTINE;HABITROL	5834011	MAY 01, 2007			
>ADD>	020076 005	NICOTINE;HABITROL	5834011	MAY 01, 2007			
>ADD>	020076 006	NICOTINE;HABITROL	5834011	MAY 01, 2007			
	020536 001	NICOTINE;NICOTROL	5501236	JUN 08, 2010			
			6098632	JUN 08, 2010			
	020714 001	NICOTINE;NICOTROL	6098632	JUN 08, 2010			
	021134 001	NITROGLYCERIN;NITROSTAT				NDF	MAY 01, 2003
	021134 002	NITROGLYCERIN;NITROSTAT				NDF	MAY 01, 2003
	021134 003	NITROGLYCERIN;NITROSTAT				NDF	MAY 01, 2003
	019921 001	OFLOXACIN;OCUFLOX	4382892	SEP 02, 2003			
			4551456	NOV 14, 2003	U-80		
	020592 001	OLANZAPINE;ZYPREXA				I-297	MAR 17, 2003
	020592 002	OLANZAPINE;ZYPREXA				I-297	MAR 17, 2003
	020592 003	OLANZAPINE;ZYPREXA				I-297	MAR 17, 2003
	020592 004	OLANZAPINE;ZYPREXA				I-297	MAR 17, 2003
	020592 005	OLANZAPINE;ZYPREXA				I-297	MAR 17, 2003
	020592 006	OLANZAPINE;ZYPREXA				I-297	MAR 17, 2003
	021086 001	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013		NCE	SEP 30, 2001
			5229382	APR 23, 2011	U-324		
			5605897	FEB 25, 2014	U-325		
			5627178	APR 23, 2011	U-326		
			5736541	MAR 24, 2015	U-328		
			5817655	APR 23, 2011	U-327		
			5817656	APR 23, 2011	U-326		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021086 002	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013		NCE	SEP 30, 2001
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
		5817656	APR 23, 2011	U-326		
021086 003	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013		NCE	SEP 30, 2001
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
		5817656	APR 23, 2011	U-326		
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
021086 004	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013		NCE	SEP 30, 2001
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
		5817656	APR 23, 2011	U-326		
020688 001	OLOPATADINE HYDROCHLORIDE;PATANOL				I-301	MAR 20, 2003
019715 001	OLSALAZINE SODIUM;DIPENTUM	4559330	JUL 31, 2004	U-58		
020103 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5344658	SEP 06, 2011			
020103 002	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5344658	SEP 06, 2011			
020103 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5344658	SEP 06, 2011		I-269	AUG 27, 2002
		5578628	JUN 24, 2006	U-44		
		4753789	JUN 24, 2006	U-44		
		4695578	JAN 25, 2005			
020605 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4695578	JAN 25, 2005	U-183		
020781 001	ONDANSETRON;ZOFRAN ODT	5955488	NOV 14, 2015			
		6063802	NOV 14, 2015			
		5578628	JUN 24, 2006	U-330		
		4695578	JAN 25, 2005	U-330		
		4753789	JUN 24, 2006	U-329		
020781 002	ONDANSETRON;ZOFRAN ODT	5955488	NOV 14, 2015			
		6063802	NOV 14, 2015			
		5578628	JUN 24, 2006	U-330		
		4695578	JAN 25, 2005	U-330		
		4753789	JUN 24, 2006	U-330		
020766 001	ORLISTAT;XENICAL	6004996	JAN 06, 2018			
021014 001	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
021014 002	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
021014 003	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020262 001	PACLITAXEL;TAXOL	6096331	FEB 22, 2013		D-57	JUN 20, 2003
	020987 001	PANTOPRAZOLE SODIUM;PROTONIX	4758579	JUL 19, 2005		NCE	FEB 02, 2005
	020819 001	PARICALCITOL;ZEMPLAR	5246925	SEP 21, 2010	U-314		
			5587497	DEC 24, 2013			
>ADD>	020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	6113944	DEC 14, 2014			
>ADD>			6121291	MAR 17, 2017	U-286		
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
>ADD>	020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	6113944	DEC 14, 2014			
>ADD>			6121291	MAR 17, 2017	U-286		
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
>ADD>	020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	6113944	DEC 14, 2014			
>ADD>			6121291	MAR 17, 2017	U-286		
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
>ADD>	020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	6113944	DEC 14, 2014			
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
>ADD>	020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	6113944	DEC 14, 2014			
>ADD>			6121291	MAR 17, 2017	U-286		
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
>ADD>	020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286		
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
>ADD>	020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286		
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
>ADD>	020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286		
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
>ADD>	020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286		
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
>ADD>	020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286		
			6062927	APR 23, 2019			
			6080759	MAY 19, 2015			
>ADD>	020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	6121291	MAR 17, 2017	U-286		
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
>ADD>	020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	6121291	MAR 17, 2017	U-286		
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021084 001	PERFLUOROPOLYMETHYLISOPROPYL ETHER;SKIN EXPOSURE REDUCT	5607979	MAY 30, 2015		NCE	FEB 17, 2005
	020698 001	POLYETHYLENE GLYCOL 3350;MIRALAX	6048901	APR 20, 2019	U-343		
	019898 002	PRAVASTATIN SODIUM;PRAVACHOL	5622985	APR 22, 2014	U-335	I-281	JUN 09, 2003
						I-304	JAN 18, 2003
						I-287	FEB 10, 2003
						I-286	JAN 18, 2003
						D-51	JAN 18, 2003
	019898 003	PRAVASTATIN SODIUM;PRAVACHOL	5622985	APR 22, 2014	U-335	I-281	JUN 09, 2003
						I-304	JAN 18, 2003
						I-287	FEB 10, 2003
						I-286	JAN 18, 2003
						D-51	JAN 18, 2003
	019898 004	PRAVASTATIN SODIUM;PRAVACHOL	5622985	APR 22, 2014	U-335	I-281	JUN 09, 2003
						I-304	JAN 18, 2003
						I-287	FEB 10, 2003
						I-286	JAN 18, 2003
						D-51	JAN 18, 2003
	019157 001	PREDNISOLONE SODIUM PHOSPHATE;PEDIAPRED	4448774	DEC 22, 2002			
>ADD>	019901 001	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
>ADD>			5061722	OCT 19, 2008	U-3		
>ADD>	019901 002	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
>ADD>			5061722	OCT 19, 2008	U-3		
>ADD>	019901 003	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
>ADD>			5061722	OCT 19, 2008	U-3		
>ADD>	019901 004	RAMIPRIL;ALTACE	5061722	OCT 19, 2008	U-3	I-310	OCT 04, 2003
>ADD>			4587258	JAN 27, 2005			
	020630 001	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583*PED	AUG 15, 2009		NPP	OCT 15, 2002
			5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
			5019583	FEB 15, 2009		PED	JAN 12, 2002
	020630 002	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5466700*PED	MAR 01, 2014	U-156	NCE	JUL 12, 2001
			5019583	FEB 15, 2009		NPP	OCT 15, 2002
			5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
			5019583*PED	AUG 15, 2009		PED	JAN 12, 2002
	020630 003	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5466700*PED	MAR 01, 2014		NCE	JUL 12, 2001
			5019583	FEB 15, 2009		NPP	OCT 15, 2002
			5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
			5019583*PED	AUG 15, 2009		PED	JAN 12, 2002
			5466700*PED	MAR 01, 2014	U-156	NCE	JUL 12, 2001
	020903 001	RIBAVIRIN;REBETOL	6051252	DEC 22, 2017			
	020835 001	RISEDRONATE SODIUM;ACTONEL				I-292	APR 14, 2003
						I-291	APR 14, 2003
						I-290	APR 14, 2003
						I-293	APR 14, 2003
>ADD>	020835 002	RISEDRONATE SODIUM;ACTONEL	5583122	DEC 10, 2013	U-222	I-292	APR 14, 2003
>ADD>						NCE	MAR 27, 2003
>ADD>						I-291	APR 14, 2003
>ADD>						I-293	APR 14, 2003
>ADD>						I-290	APR 14, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020588 001	RISPERIDONE;RISPERDAL	5453425	JUL 11, 2014			
			5616587	JUL 11, 2014			
	020659 001	RITONAVIR;NORVIR	6037157	JUN 26, 2016			
			5674882	OCT 07, 2014			
			5886036	DEC 29, 2012			
			5648497	JUL 15, 2014		NCE	MAR 01, 2001
>ADD>	020945 001	RITONAVIR;NORVIR	5846987	DEC 29, 2012	U-347		
>ADD>			5541206	JUL 30, 2013	U-348		
>ADD>			5635523	JUN 03, 2014	U-347		
>ADD>			4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
	020823 003	RIVASTIGMINE TARTRATE;EXELON	5602176	FEB 11, 2014	U-322		
			4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
	020823 004	RIVASTIGMINE TARTRATE;EXELON	5602176	FEB 11, 2014	U-322		
			4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
	020823 005	RIVASTIGMINE TARTRATE;EXELON	5602176	FEB 11, 2014	U-322		
			4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
	020823 006	RIVASTIGMINE TARTRATE;EXELON	5602176	FEB 11, 2014	U-322		
			4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
	021025 001	RIVASTIGMINE TARTRATE;EXELON	5602176	FEB 11, 2014	U-322		
	020864 001	RIZATRIPTAN BENZOATE;MAXALT	5602162	FEB 11, 2014			
	020864 002	RIZATRIPTAN BENZOATE;MAXALT	5602162	FEB 11, 2014			
	021042 001	ROFECOXIB;VIOXX	6063811	MAY 16, 2017	U-266		
	021042 002	ROFECOXIB;VIOXX	6063811	MAY 16, 2017	U-266		
>ADD>	021042 003	ROFECOXIB;VIOXX				NCE	MAY 20, 2004
	021052 001	ROFECOXIB;VIOXX	6063811	MAY 16, 2017	U-266		
	021052 002	ROFECOXIB;VIOXX	6063811	MAY 16, 2017	U-266		
	021071 002	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
			5741803	APR 21, 2015	U-329		
	021071 003	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
			5741803	APR 21, 2015	U-329		
	021071 004	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
			5741803	APR 21, 2015	U-329		
	020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-286		
			4940731	AUG 30, 2009	U-312		
	021179 001	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
			5667775	SEP 16, 2014	U-246		
	021179 002	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
			5667775	SEP 16, 2014	U-246		
	020478 001	SEVOFLURANE;ULTANE	5990176	JAN 27, 2017		NCE	JUN 07, 2000
			6074668	JAN 09, 2018		PED	DEC 07, 2000
			5990176*PED	JUL 27, 2017			
			6074668*PED	JUL 09, 2018			
	020280 006	SOMATROPIN RECOMBINANT;GENOTROPIN	4968299	JUN 28, 2008		I-302	JUN 20, 2003
						ODE	JUN 20, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020280 007	SOMATROPIN RECOMBINANT;GENOTROPIN	4968299	JUN 28, 2008		I-302	JUN 20, 2003
						ODE	JUN 20, 2007
	020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 004	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				I-302	JUN 20, 2000
						ODE	JUN 20, 2007
	020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 010	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 011	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5716338	FEB 10, 2015		I-302	JUN 20, 2003
			5435076	APR 16, 2013		ODE	JUN 20, 2007
	020280 012	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 013	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	019721 001	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
	019721 002	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
	019676 001	SOMATROPIN RECOMBINANT;NUTROPIN				D-55	APR 13, 2003
						M-2	DEC 01, 2002
	019676 002	SOMATROPIN RECOMBINANT;NUTROPIN				D-55	APR 13, 2003
						M-2	DEC 01, 2002
	020522 001	SOMATROPIN RECOMBINANT;NUTROPIN AQ				D-55	APR 13, 2003
						M-2	DEC 01, 2002
	021075 001	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	6051259	DEC 02, 2012	U-340		
	021075 002	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	6051259	DEC 02, 2012	U-340		
	021075 003	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	6051259	DEC 02, 2012	U-340		
	021151 001	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
	021151 002	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
	021151 003	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
>ADD>	007073 002	SULFASALAZINE;AZULFIDINE EN-TABS				I-308	AUG 18, 2003
	020256 001	TECHNETIUM TC-99M BICISATE KIT;NEUROLITE	5431900	JUL 11, 2012	U-336		
	019785 001	TECHNETIUM TC-99M SESTAMIBI KIT;CARDIOLITE	4894445	JAN 16, 2007	U-337		
			5324824	JAN 16, 2007			
			4885100	SEP 11, 2007			
			4988827	JAN 29, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019785 003	TECHNETIUM TC-99M SESTAMIBI KIT;MIRALUMA	4452774	SEP 09, 2004			
			4894445	JAN 16, 2007	U-337		
			5324824	JAN 16, 2007			
			4885100	SEP 11, 2007			
			4988827	JAN 29, 2008			
	021124 001	TERBINAFINE HYDROCHLORIDE;LAMISIL AT	4680291	JUL 14, 2004	U-73		
			4755534	DEC 30, 2006	U-73		
			5681849	OCT 28, 2014			
	021015 001	TESTOSTERONE;ANDROGEL				NDF	FEB 28, 2003
	020484 001	TINZAPARIN SODIUM;INNOHEP				NCE	JUL 14, 2005
	020771 001	TOLTERODINE TARTRATE;DETROL	5559269	MAY 05, 2015	U-318		
	020771 002	TOLTERODINE TARTRATE;DETROL	5559269	MAY 05, 2015	U-318		
	020281 001	TRAMADOL HYDROCHLORIDE;ULTRAM				PED	SEP 03, 2000
						PED	FEB 21, 2002
						NCE	MAR 03, 2000
						D-44	AUG 21, 2001
	020281 002	TRAMADOL HYDROCHLORIDE;ULTRAM				PED	FEB 21, 2002
						PED	SEP 03, 2000
						NCE	MAR 03, 2000
						D-44	AUG 21, 2001
	074973 001	TRIMETHOPRIM HYDROCHLORIDE;PRIMSOL	5763449	AUG 07, 2016			
			5962461	AUG 07, 2016			
	020326 001	TRIMETREXATE GLUCURONATE;NEUTREXIN	6017922	MAY 18, 2018			
	020326 002	TRIMETREXATE GLUCURONATE;NEUTREXIN	6017922	MAY 18, 2018			
	020715 001	TRIPTORELIN PAMOATE;TRELSTAR DEPOT	5134122	JUL 20, 2010		NCE	JUN 15, 2005
			5225205	JUL 20, 2010			
			5192741	MAR 09, 2010			
	020719 001	TROGLITAZONE;PRELAY	6046202	SEP 15, 2013	U-317		
	020719 002	TROGLITAZONE;PRELAY	6046202	SEP 15, 2013	U-317		
	020719 003	TROGLITAZONE;PRELAY	6046202	SEP 15, 2013	U-317		
	020720 001	TROGLITAZONE;REZULIN	6046202	SEP 15, 2013	U-317		
	020720 002	TROGLITAZONE;REZULIN	6046202	SEP 15, 2013	U-317		
	020720 003	TROGLITAZONE;REZULIN	6046202	SEP 15, 2013	U-317		
>ADD>	020759 001	TROVAFLOXACIN MESYLATE;TROVAN	5164402	DEC 18, 2011	U-282		
>ADD>	020759 002	TROVAFLOXACIN MESYLATE;TROVAN	5164402	DEC 18, 2011	U-282		
	021214 001	UNOPROSTONE ISOPROPYL;RESCULA	5001153	SEP 19, 2008		NCE	AUG 03, 2005
			5151444	MAR 19, 2008	U-333		
			5166178	NOV 24, 2009	U-333		
			5212200	MAY 18, 2010	U-333		
			5208256	MAY 21, 2011	U-333		
			5221763	JUN 22, 2010			
	020552 001	VERAPAMIL HYDROCHLORIDE;COVERA-HS	5232705	AUG 31, 2010			
			5200196	JAN 22, 2008			
			5141752	JUN 27, 2006			
			5082668	JAN 21, 2009			
			5030456	NOV 07, 2008			
			4946687	OCT 02, 2007			
			5785994	OCT 22, 2009	U-315		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020552 002	VERAPAMIL HYDROCHLORIDE;COVERA-HS	5232705	AUG 31, 2010			
		5200196	JAN 22, 2008			
		5141752	JUN 27, 2006			
		5082668	JAN 21, 2009			
		5030456	NOV 07, 2008			
		4946687	OCT 02, 2007			
		5785994	OCT 22, 2009	U-315		
021119 001	VERTEPORFIN;VISUDYNE				NCE	APR 12, 2005
020547 001	ZAFIRLUKAST;ACCOLATE	5583152	SEP 26, 2010			
020547 003	ZAFIRLUKAST;ACCOLATE	4859692	SEP 26, 2010		NCE	SEP 26, 2001
		5294636	DEC 11, 2011		I-268	SEP 17, 2002
		5319097	DEC 11, 2011		NS	SEP 17, 2002
		5482963	JAN 09, 2013			
		5583152	SEP 26, 2010			
		5612367	MAR 18, 2014	U-189		
021036 001	ZANAMIVIR;RELENZA				I-294	APR 26, 2003
020789 001	ZONISAMIDE;ZONEGRAN				NCE	MAR 27, 2005

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 20TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

NPP	**NEW PATIENT POPULATION**

REFERENCES

NEW DOSING SCHEDULE

D-51	**OPTIONAL STARTING DOSE OF 40MG/DAY**
D-52	**ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY**
D-53	**USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE**
D-54	**USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS**
D-55	**ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)**
D-56	**ADDITION OF POSTPRANDIAL DOSING**
D-57	**3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER**
D-58	**CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION**
D-59	**REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY**
D-60	**ADDITION OF A POST-OPERATIVE DOSING REGIMEN**
D-61	**ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS**
D-62	**ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS**

NEW INDICATION

I-283	**TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS**
I-286	**TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III**
I-287	**USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH**
I-288	**CHANGES SEVERAL SECTIONS OF THE PACKAGE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE**
I-289	**USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL**
I-290	**TREATMENT OF CORTICOSTEOID-INDUCED OSTEOPOROSIS**
I-291	**PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS**

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-292	TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-293	TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-294	TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS
I-295	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS
I-296	LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY
I-297	SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-298	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA
I-299	USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM
I-300	PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE
I-301	TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS
I-302	TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME
I-303	INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS
I-304	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV
I-305	TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
I-306	INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE
I-307	NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES
I-308	TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS
I-309	INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-310	REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES

MISCELLANEOUS EXCLUSIVITY CODES

M-2	APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
M-3	ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-266	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA
U-309	TREATING SJOEGREN SYNDROME
U-310	TREATMENT OF XEROSTOMIA
U-311	HORMONE REPLACEMENT
U-312	PANIC DISORDER OBSESSIVE-COMPULSIVE DISORDER POSTTRAUMATIC STRESS DISORDER
U-313	TREATMENT OF CONGESTIVE HEART FAILURE
U-314	METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY
U-315	METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
U-316	METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
U-317	METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE
U-318	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
U-319	TREATMENT OF MICROBIAL INFECTIONS
U-320	INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA
U-321	REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS
U-322	TREATMENT OF ALZHEIMER'S DEMENTIA
U-323	USE AS A BILE ACID SEQUESTRANT
U-324	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE
U-325	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE
U-326	METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER
U-327	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITIONS EMPLOYING OLANZAPINE
U-328	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH
U-329	USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-330	TREATMENT OF NAUSEA AND VOMITING
U-331	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-332	TREATMENT OR PREVENTION OF BRONCHOSPASM
U-333	METHOD OF TREATING OCULAR HYPERTENSION
U-334	TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
U-335	USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
U-336	DIAGNOSTIC RADIOIMAGING
U-337	USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI
U-338	METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME
U-339	PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN
U-340	THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN
U-341	METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER
U-342	METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-343	REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION
U-344	METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR
U-345	RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION
U-346	METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS METABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR
U-347	METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS
U-348	METHOD OF USE FOR INHIBITING HIV INFECTION
U-349	METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION
U-350	PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-351	INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIR
U-352	INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-353	PREVENTION AND TREATMENT OF OSTEOPOROSIS

*U.S. Government Printing Office: 2000 — 472-432/21003

New 21st Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 8367

Charge your order. It's easy!

☐ **Yes,** enter my subscription as follows:

_subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $101.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐–☐

☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(____)_____
Daytime phone including area code

_____
Purchase Order No. (optional)

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature)

(10/00)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.